Name: IASLC 2026 World Conference on Lung Cancer
Start: 2026-09-12
End: 2026-09-15
Location: Seoul, Republic of Korea

Ranked by reach

Most-Discussed Trials

The trials global KOLs are talking about most ahead of WCLC 2026, ranked by the reach of the posts naming each one. Click a trial to read the posts behind it.

1MAVERICK28.6K impressions12.4K primary · 16.3K preview173 engagements8 posts · 7 voices▾

DDrew Moghanaki@DrewMoghanaki

The PCI question has been answered in a contemporary phase III RCT. Final results remain embargoed until 9/13. #WCLC26 @PDBrownOnc @bslotman https://t.co/ABMuPK4xCV

10K impressions95 likes23 reposts2026-08-20

[Slide 1] PL02. Presidential Symposium 1 Including Lectureship Award Presentations 4 Sunday, September 13, 2026 at 8:00 AM KST / UTC +9 - 2h 30m Plenary, Hall D2, 3F Presentations in this session Q&A PL02.01. SWOG S1827 MAVERICK: Phase III Trial of Brain MRI Surveillance +/- Prophylactic Cranial Irradiation for Small- Cell Lung Cancer C.G. Rusthoven¹,², M.W. Redman³, P.D. Brown⁴, J.S. Wefel⁵, J. Miao⁶, M-H. Hsieh³, J. Honce¹, J.M. Unger³, N.L. Henry⁷, A.A. Patel⁸, D.Y. Gelblum⁹, J. Greenland¹⁰ D. Moghanaki¹¹, T. À Biswas¹², L. Alder¹³, N.S. McCall¹⁴, J. Gray¹⁵, K. Kelly¹⁶

ggilberto lopes@GlopesMd

2/6 MAVERICK / SWOG S1827
The question: in the MRI era, do patients with SCLC still need prophylactic cranial irradiation?
(both limited and extensive stage)

We know: PCI reduces brain metastases, but cognition and the role of modern MRI surveillance remain major concerns.

At WCLC: Can MRI surveillance safely replace PCI without compromising survival — and what happens to brain control, cognitio

2.4K impressions11 likes3 reposts2026-08-21

From session previews

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

🔥 #WCLC26 Presidential Symposium 1
🇰🇷 Sunday, September 13, 2026

A major session spanning SCLC and non-driver NSCLC, with several practice-changing Phase 3 readouts:
🧠 SWOG S1827 MAVERICK
Brain MRI surveillance ± PCI in SCLC

🧩 TAISHAN-302
Tam-Peli, a B7-H3 ADC, vs topotecan in relapsed SCLC

🎯 ARTEMIS-008
Risvutatug Rezetecan vs topotecan in relapsed SCLC

🫁 EVOKE-03 / KEYNOTE D46 Sacituzumab Go

6.2K impressions27 likes10 reposts2026-08-19

[Slide 1] IASLC 2026 World Conference 2026 ) on Lung Cancer Sunday, September 13, 2026 at 8:00 AM KST WCLC 2026 Presidential Symposium 1 PL02 Including Lectureship Award Presentations 01 PL02.01 02 PL02.03 SWOG S1827 TAISHAN-302 MAVERICK Phase III Trial of Brain MRI Y. Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Surveillance +/- Prophylactic Versus Topotecan in Cranial Irradiation for Relapsed SCLC: A Randomized, Small-Cell Lung Cancer Open-Label, Phase 3 Study 03 PL02.04 04 PL02.06 ARTEMIS-008 EVOKE-03 / Risvutatug Rezetecan KEYNOTE D46 (a B7-H3-Directed ADC) Primary Results from Phase 3: Versus Topotecan in Sacituzumab Govitecan + Relapsed SCLC: Primary Pembrolizumab in PD-L1 Results of Phase 3 TPS >=50% Metastatic NSCLC

UUğur Özkerim@UOzkerim

WCLC 2026 is getting closer! 🇰🇷🫁

Eight studies from the Presidential Symposia that I’ll be watching closely in Seoul.

Which one are you most excited about?

#WCLC2026 @IASLC
@OncoAlert @GlopesMd @weoncologists @MedwatchKate @StephenVLiu @ManuelDomine @MedwatchKate @RManochakian

4.2K impressions51 likes18 reposts2026-08-20

[Slide 1] IASLC 2026 World Conference 2026 on Lung Cancer WCLC 2026 Uniting Asia, Inspiring the World September 12-15, 2026 Seoul, Korea PRESIDENTIAL SYMPOSIUM 1 SUNDAY, SEPTEMBER 13, 2026 8:00 AM KST 01 PL02.01 SWOG S1827 MAVERICK Phase III Trial of Brain MRI Surveillance +/- Prophylactic Cranial Irradiation for Small-Cell Lung Cancer 02 PL02.03 TAISHAN-302 Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed SCLC: A Randomized, Open-Label, Phase 3 Study 03 PL02.04 ARTEMIS-008 Risvutattug Rezetecan (a B7-H3-Directed ADC) Versus Topotecan in Relapsed SCLC: BRS Primary Results of Phase 3 04 PL02.06 EVOKE-03 / KEYNOTE D46 Primary Results from Phase 3: Sacituzumab Govitecan + Pembrolizumab in PD-L1 TPS >50% Metastatic NSCLC PRESIDENTIAL SYMPOSIUM 2 MONDAY, SEPTEMBER 14, 2026 8:00 AM KST 01 PL03.01 ADAURA Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Exploratory 8-Year Overall Survival Landmark Update 02 PL03.03 DOI PAPILLON Exon First-line Amivantamab-Chemotherapy vs Chemotherapy 20 in NSCLC with EGFR Exon 20 Insertions: Overall Survival Results from PAPILLON 03 PL03.04 REZILIENT 3 Zipalertinib Plus Chemotherapy for 1st Line NSCLC with EGFR Exon 20 Insertions: Results from the Phase 3 Trial (REZILIENT 3) 04 PL03.06 ARROS-1 Zidesamtinib in TKI-naïve Patients with Advanced/Metastatic ROS1+ NSCLC: ARROS-1 Efficacy and Safety Data See you in Seoul! wclc2026.org @IASLC in IASLC #WCLC2026

ggilberto lopes@GlopesMd

WCLC 2026 Presidential Symposium 1 looks like a fascinating Sunday morning in Seoul.

Four phase III trials. One could change a decades-old approach to brain radiation, two test a potentially important new drug class in small-cell lung cancer, and one may help explain why promising phase II data did not translate into a positive phase III study.

Here is what we already know — and what I will be w

2.4K impressions17 likes9 reposts2026-08-24

[Slide 1] WCLC 2026 Presidential Symposium 1 Sunday, September 13, 2026 What we know now - and what we will learn in Seoul 1. MAVERICK / SWOG S1827 2. TAISHAN-302 Brain MRI surveillance + prophylactic Tam-peli (B7-H3 ADC) VS topotecan cranial irradiation in SCLC in relapsed SCLC What we know What WCLC will tell us What we know What WCLC will tell us PCI reduces brain metastases Can MRI surveillance safely Early-phase activity has OS, PFS, durability, replace PCI? been encouraging and toxicity Cognition and MRI-era surveillance remain central Impact on survival, brain control, No public phase III Is B7-H3 ready for prime concerns cognition, and QoL topline result yet time in SCLC? 3. ARTEMIS-008 4. EVOKE-03 / KEYNOTE-D46 Risvutatug rezetecan (B7-H3 ADC) VS Sacituzumab govitecan + pembrolizumab vs topotecan in relapsed SCLC, in China pembrolizumab in metastatic NSCLC, PD-L1 >50% What we know What WCLC will tell us What we know What WCLC will tell us Phase III met its primary How large is the benefit? PFS numerically favored Why did phase II promise not overall-survival endpoint the combination translate into phase III success? HR, median OS, PFS, Benefit described as durability, and safety The difference was not OS, subgroup signals, statistically significant and statistically significant; and safety clinically meaningful study was discontinued Can B7-H3 ADCs establish a new What can a negative phase III ? Big questions Can we safely use less radiation? treatment class in SCLC? trial teach us?

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Plenary Session
🔥SWOG S1827 MAVERICK: Phase III Trial of Brain MRI Surveillance +/- Prophylactic Cranial Irradiation for Small-Cell Lung Cancer
🎙️Dr. Chad G. Rusthoven
🔢PL02.01
☑️NCT04155034
🔗 https://t.co/icbDk1Zjnh
@OncoAlert @Larvol @IASLC https://t.co/ZOmILs19Ds

1.2K impressions10 likes3 reposts2026-08-20

[Slide 1] PL02.01. SWOG S1827 MAVERICK: Phase III Trial of Brain MRI Surveillance +/- Prophylactic Cranial Irradiation for Small-Cell Lung Cancer C.G. Rusthoven M.W. Redman³, P.D. Brown⁴, J.S. Wefel⁵, J. Miao⁶, M-H. Hsieh³, J. Honce¹, J.M. Unger³, N.L. Henry⁷, A.A. Patel⁸, D.Y. Gelblum⁹, J. Greenland¹⁰, D. Moghanaki¹¹, T. Biswas L. Alder¹³, N.S. McCall¹⁴, J. Gray¹⁵, K. Kelly¹⁶ University of Colorado School of Medicine, Aurora/CO/USA, University of North Carolina School of Medicine, Chapel Hill/NC/USA, ³Fred Hutchinson Cancer Center, Seattle/WA/USA Mayo Clinic, Rochester/MN/USA, 5MD Anderson Cancer Center, Houston/TX/USA, ⁶SWOG Statistics and Data Management Center, Seattle/WA/USA, University of Michigan, Ann Arbor/MI/USA, 8 Yale University School of Medicine, New Haven/CT/USA, Memorial Sloan Kettering Cancer Center, New York/NY/USA, 10Memorial University of Newfoundland, St Johns/NL/CA, University of California, Los Angeles, Los Angeles/CA/USA, 12 University of Florida College of Medicine, Gainesville/FL/USA, 13 Duke University Medical Center, Durham/NC/USA, 14 UPMC Hillman Cancer Center, Pittsburgh/PA/USA, 1⁵H. Lee Moffitt Cancer Center, Tampa/FL/USA, ¹⁶International Association for the Study of Lung Cancer, Denver/CO/USA View abstract @ of View biography

2EVOKE-0324.8K impressions920 primary · 23.8K preview14 engagements8 posts · 6 voices▾

ggilberto lopes@GlopesMd

5/6 EVOKE-03 / KEYNOTE-D46

Sacituzumab govitecan + pembrolizumab vs pembrolizumab alone in untreated metastatic NSCLC with PD-L1 ≥50%.

The early data looked promising.

But phase III tells a different story:

❌ PFS numerically favored the combination but did not reach statistical significance, and the study was discontinued.

At WCLC I want to understand why — and what the OS, subgroup and safet

920 impressions7 likes3 reposts2026-08-21

From session previews

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

6.2K impressions27 likes10 reposts2026-08-19

UUğur Özkerim@UOzkerim

4.2K impressions51 likes18 reposts2026-08-20

GGiannis Mountzios@g_mountzios

🌟 Truly honored that our work has been selected for presentation at the Presidential Symposium 1 of the World Lung Cancer Conference #WCLC26 in Seoul:
⏰ Sunday, 13 September 08:00-10:30 KST
🗒️ Presidential Symposium 1
📌 Plenary, Hall D2, 3F
Primary analysis of the global, randomized phase III EVOKE-03/KEYNOTE D46 clinical trial on the combination of Sacituzumab Govitecan plus pembro vs pembro mono

4.2K impressions34 likes8 reposts2026-08-20

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

1/2
🚨 Several #WCLC26 Presidential Symposium trials already have topline press releases 👀

🙌 ARTEMIS-008 | Risvutatug Rezetecan
• Phase 3 in relapsed SCLC
• Met the primary endpoint of OS vs. topotecan
• Statistically significant and clinically meaningful OS benefit!
🔗 https://t.co/WavE0BuSbb

🤦‍♂️ EVOKE-03 / KEYNOTE-D46 | Sacituzumab Govitecan + pembrolizumab
• 1L PD-L1 TPS ≥50% metastatic NSCLC

3.9K impressions12 likes1 reposts2026-08-20

3ARTEMIS-00824K impressions793 primary · 23.2K preview9 engagements9 posts · 7 voices▾

ggilberto lopes@GlopesMd

4/6 ARTEMIS-008

Another B7-H3 ADC, risvutatug rezetecan, versus topotecan.

Here we already know something important:

✅ The phase III trial met its primary overall-survival endpoint, with a statistically significant and clinically meaningful benefit.

At WCLC the question isn’t “did it work?”

It’s how much did it work?

HR, median OS, absolute benefit, PFS, durability and safety will matter.

793 impressions6 likes1 reposts2026-08-21

From session previews

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

6.2K impressions27 likes10 reposts2026-08-19

UUğur Özkerim@UOzkerim

4.2K impressions51 likes18 reposts2026-08-20

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

3.9K impressions12 likes1 reposts2026-08-20

KKazuo@kayaba_mo

【製薬・バイオ情報】
WCLC 2026
9月12～15日、韓国・ソウルのCOEXで開催される世界最大級の肺がん学会。

最大のテーマは、
「ADCが後治療の薬から、一次治療・標準治療へどこまで上がれるか」。

効くかではなく、現在の標準を破れるかを見る大会。

①最大の注目はエンハーツのDESTINY-Lung04。

9月14日の「Presidential Symposium 2」で主要結果が発表されます。公式演題番号はPL03.08。

DESTINY-Lung04は、HER2 exon 19/20変異NSCLCの一次治療で、

エンハーツ単剤
vs
キイトルーダ＋プラチナ＋ペメトレキセド

を直接比較したPhase 3。

既にPFSの有意かつ臨床的に意味のある改善が開示済み。詳細と安全性が強ければ、エンハーツが2次治療から1次治療へ上がります。

②9月13日は、再発小細胞肺がん

2.9K impressions22 likes2 reposts2026-08-23

4PAPILLON20.7K impressions1.8K primary · 18.9K preview27 engagements8 posts · 6 voices▾

ggilberto lopes@GlopesMd

3/6 PAPILLON

1L amivantamab + chemotherapy changed treatment for EGFR exon20ins NSCLC.

What we know:

PFS: 11.4 vs 6.7 months
HR 0.40

ORR: 73% vs 47%

The initial OS analysis showed a favorable but immature trend.

At WCLC: mature overall survival.

That is the missing piece.

1.1K impressions6 likes4 reposts2026-08-22

ggilberto lopes@GlopesMd

4/6 ⚡ REZILIENT3

And immediately after PAPILLON comes a potential challenger:

zipalertinib + chemotherapy in first-line EGFR exon20ins NSCLC.

We already know from the public topline announcement:

✅ REZILIENT3 met its primary PFS endpoint.

But we don’t know the numbers.

At WCLC: the HR, median PFS, response, CNS activity, safety and OS maturity.

Back-to-back with PAPILLON, this should be fas

735 impressions7 likes2 reposts2026-08-22

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Plenary Session
🔥PAPILLON: First-Line Amivantamab-Chemotherapy vs Chemotherapy in NSCLC With EGFR Exon 20 Insertions: Overall Survival
🎙️ @chulkimMD
🔢PL03.03
☑️NCT04538664
🔗 https://t.co/mYsNwaWQUZ
@OncoAlert @Larvol @IASLC @EGFRResisters @Exon20Group https://t.co/1Q6iRvY46I https://t.co/poufzTii55

7.3K impressions51 likes14 reposts2026-08-20

[Slide 1] PL03.03. First-line Amivantamab-chemotherapy VS Chemotherapy in NSCLC with EGFR Exon 20 Insertions: Overall Survival from PAPILLON C. Kim¹, K-J. Tang², B.C. Cho³, L. Paz-Ares⁴, S. Cheng⁵, M. Nishio⁶, M. Thiagarajan⁷, J.W. Goldman⁸, J-Y. Hung⁹, J. Mourão Dias¹⁰, S. Popat¹¹, J.K. Sabari¹², N. Girard¹³, A.S. Mansfield¹⁴, K. Park¹⁵, R.E. Sanborn¹⁶, J. Schuchard N. Buyukkaramikli¹⁸, N. Perualila¹⁸, A. Bhattacharya¹⁹ P. Barala²⁰, M. Gamil²⁰, S. Gandhy²⁰, J. Man²¹, S. Shah20, C. Zhou²² 1 Division of Hematology and Oncology, Georgetown Cancer Institute, Washington/DC/USA Division of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Sun Yat-sen University, Guangzhou/CN ³Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR 4Hospital Universitario 12 de Octubre, Madrid/ES ⁵Sunnybrook Odette Cancer Centre, Toronto/ON/CA ⁶Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo/JP, ,7 Hospital Kuala Lumpur, Kuala Lumpur/MY ⁸David Geffen School of Medicine, University of California Los Angeles, Los Angeles/CA/USA ⁹Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung/TW, 10 Barretos Cancer Hospital, Barretos/BR 11 Royal Marsden Hospital NHS Foundation Trust; The Institute of Cancer Research, London/GB, ¹²NYU Langone Health, New York/NY/USA, 13 Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France and Paris Saclay University, Université de Versailles Saint- Quentin-en-Yvelines, Versailles/FR, 14 Mayo Clinic, Rochester/MN/USA, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR, 16 Earle A. Chiles Research Institute, Providence Cancer Institute of Oregon, Portland/OR/USA, 17 Johnson & Johnson, Horsham/PA/USA 18 Johnson & Johnson, Beerse/BE, 19 Johnson & Johnson, High Wycombe/GB, 20 Johnson & Johnson, Spring House/PA/USA 21 Johnson & Johnson, Raritan/NJ/USA, Shanghai East Hospital, Shanghai/CN View abstract @ of View biography

UUğur Özkerim@UOzkerim

4.2K impressions51 likes18 reposts2026-08-20

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

🧬 #WCLC26 Presidential Symposium 2
🇰🇷 Monday, September 14, 2026

This one is all about oncogene-driven NSCLC, with important updates across EGFR and ROS1:
🔹 ADAURA 8-year OS landmark update for adjuvant osimertinib in resected EGFR-mutant NSCLC

🔹 PAPILLON OS with 1L amivantamab + chemotherapy in EGFR exon 20 insertion NSCLC

🔹 REZILIENT 3 Phase 3 results of 1L zipalertinib + chemotherapy in EGF

4.1K impressions33 likes9 reposts2026-08-19

[Slide 1] IASLC Januy 2026 World Conference 2026 ) on Lung Cancer Monday, September 14, 2026 at 8:00 AM KST WCLC 2026 Presidential Symposium 2 PL03 Including Lectureship Award Presentations 01 PL03.01 02 PL03.03 ADAURA PAPILLON Adjuvant Osimertinib in First-line Amivantamab- Resected EGFR-Mutated Exon chemotherapy vs Chemotherapy Stage IB-IIIA NSCLC: 20 in NSCLC with EGFR Exon 20 ADAURA Exploratory 8-year Insertions: Overall Survival Overall Survival Landmark Update from PAPILLON 03 PL03.04 04 PL03.06 REZILIENT 3 ARROS-1 Zipalertinib Plus Chemotherapy Zidesamtinib in TKI-naive for 1st Line NSCLC with Patients with Advanced/ EGFR Exon 20 Insertions: Metastatic ROS1+ NSCLC: Results From the Phase 3 ARROS-1 Efficacy and Trial (REZILIENT 3) Safety Data a

ggilberto lopes@GlopesMd

Here we go with our second tweet on @iaslc #wclc26 prep!

1/6 If Presidential Symposium 1 at #WCLC26 is eclectic, Symposium 2 has a remarkably clear theme:

Targeted therapy moving earlier — and getting better.

ADAURA → PAPILLON → REZILIENT3 → ARROS-1.

Here’s what we already know — and what Monday morning in Seoul should tell us

@OncoAlert @OncBrothers @oncodaily @Jani_Chinmay @Latinamd @COlaza

1.9K impressions22 likes13 reposts2026-08-22

[Slide 1] See you 111 Seoul see You in Seoul, Republic of horea I 2026 IASLC 2026 World WCLC 2026 I SEPTEMBER 12 - 15, 2026 Conference on Lung Cancer SEPTEMBER 12 15, 2026 wclc.iaslc.org f in D SEOUL, REPUBLIC OF KOREA FULL SESSION INFORMATION > View session PL03. Presidential Symposium 2 Including Lectureship Award Presentations 1 Monday, September 14, 2026 at 8:00 AM KST / UTC +9 I 2h 30m Plenary, Hall D2, 3F

5TAISHAN-30219.3K impressions595 primary · 18.8K preview8 engagements8 posts · 7 voices▾

ggilberto lopes@GlopesMd

3/6 TAISHAN-302

Tam-peli is a B7-H3 antibody-drug conjugate being compared with topotecan in relapsed SCLC.

We know: Early-phase activity has been very encouraging.

We don’t yet know publicly: whether the phase III trial is positive.

At WCLC: OS, PFS, response durability and toxicity — and whether B7-H3 is truly ready for prime time in SCLC.

595 impressions5 likes1 reposts2026-08-21

From session previews

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

6.2K impressions27 likes10 reposts2026-08-19

UUğur Özkerim@UOzkerim

4.2K impressions51 likes18 reposts2026-08-20

KKazuo@kayaba_mo

2.9K impressions22 likes2 reposts2026-08-23

ggilberto lopes@GlopesMd

2.4K impressions17 likes9 reposts2026-08-24

6ADAURA17.7K impressions1.3K primary · 16.4K preview25 engagements7 posts · 6 voices▾

ggilberto lopes@GlopesMd

2/6 ADAURA — 8-year update

We already know that 3 years of adjuvant osimertinib improves DFS and OS after resection of EGFR-mutant NSCLC.

Now comes the fascinating long-term question:

Does that benefit remain durable years after osimertinib has stopped?

At WCLC: the 8-year OS landmark and the shape of those survival curves.

This is less about establishing the standard — and more about underst

1.3K impressions16 likes4 reposts2026-08-22

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Plenary Session
🔥ADAURA: Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update
🎙️ @DrRoyHerbst
🔢PL03.01
☑️NCT02511106
🔗 https://t.co/mYsNwaWQUZ
@OncoAlert @Larvol @IASLC @EGFRResisters https://t.co/qu6lBMcccp https://t.co/oAUtRXpr9u

4.8K impressions35 likes11 reposts2026-08-20

[Slide 1] PL03.01. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: ADAURA Exploratory 8-year Overall Survival Landmark Update R.S. Herbst¹, M. Majem², T. John³, C. Grohé⁴, J. Wang⁵, J.W. Goldman⁶, S. Lu7, F.A. Shepherd⁸, T. Kato⁹, K. Aokage¹⁰, K. Laktionov¹¹, M-F. Wu¹², C. Akewanlop¹³, H. Vinh Vu¹⁴, K.H. Lee¹⁵, X. Huang¹⁶, E. Armenteros Monterroso¹⁷, H. Jiang¹⁸, Y- L. Wu19 1 Dartmouth Cancer Center, Lebanon/NH/USA 2Department of Medical Oncology, Institut de Recerca Sant Pau (IR SANTPAU), Hospital de la Santa Creu i Sant Pau, Barcelona/ES ³Department of Medical Oncology and Hematology, Peter MacCallum Cancer Centre; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne/AU 4Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin/DE ⁵Cancer Hospital Chinese Academy of Medical Sciences, Beijing/CN, 6 David Geffen School of Medicine at University of California Los Angeles, Los Angeles/CA/USA Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai/CN ⁸Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto/ON/CA, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama/JP, ¹⁰Division of Thoracic Surgery, National Cancer Center Hospital East, Chiba/JP, Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, Moscow/RU, 2Department of Medical Oncology, Chung Shan Medical University Hospital, Taichung/TW, Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok/TH 14 Department Thoracic Surgery, Cho Ray Hospital, Ho Chi Minh City/VN Department of Internal Medicine, Chungbuk National University Hospital, Cheongju/KR 16 Biometrics, Late-stage Development, Oncology R&D, AstraZeneca, Cambridge/GB 17 Late- stage Development, Oncology R&D, AstraZeneca, Barcelona/ES, 18 Late-stage Development, Oncology R&D, AstraZeneca, Gaithersburg/MD/USA, ¹⁹Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou/CN View abstract JO View biography

UUğur Özkerim@UOzkerim

4.2K impressions51 likes18 reposts2026-08-20

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

4.1K impressions33 likes9 reposts2026-08-19

ggilberto lopes@GlopesMd

1.9K impressions22 likes13 reposts2026-08-22

7REZILIENT316.3K impressions855 primary · 15.4K preview13 engagements10 posts · 9 voices▾

ggilberto lopes@GlopesMd

735 impressions7 likes2 reposts2026-08-22

BBusiness-News-Today.com@BNTBriefing

@TaihoOncology and @CullinanTx prepare pivotal zipalertinib data for WCLC 2026 https://t.co/P14yPAPduA Zipalertinib’s pivotal REZILIENT3 data will debut at WCLC 2026 after the first-line lung cancer trial met its PFS endpoint. #Zipalertinib #REZILIENT3 #WCLC2026 #IASLC #NSCLC #EGFR #CullinanTherapeutics #TaihoOncology

120 impressions1 likes0 reposts2026-08-20

From session previews

UUğur Özkerim@UOzkerim

4.2K impressions51 likes18 reposts2026-08-20

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

4.1K impressions33 likes9 reposts2026-08-19

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Plenary Session
🔥REZILIENT3: Zipalertinib Plus Chemotherapy for 1st Line NSCLC With EGFR Exon 20 Insertions: Results From the Phase 3 Trial
🎙️ @danieltanmd
🔢PL03.04
☑️NCT05973773
🔗 https://t.co/mYsNwaWQUZ
@OncoAlert @Larvol @IASLC @EGFRResisters @Exon20Group https://t.co/y5CL5e57jr https://t.co/HbqEivMATW

3.1K impressions29 likes6 reposts2026-08-20

[Slide 1] PL03.04. Zipalertinib Plus Chemotherapy for 1st Line NSCLC with EGFR Exon 20 Insertions: Results From the Phase 3 Trial (REZILIENT 3) D.S. Tan¹, P. Danchaivijitr², Y. Shinno³, C. Ho⁴,⁵, J. Zugazagoitia⁶, T. Inoue⁷, G-W. Lee⁸, A.J.d. Langen⁹, A. Sezer¹⁰, A. Pender¹¹, C. Dooms¹², F. Cappuzzo¹³, Y. Fujiwara Y. Runglodvatana¹ A.C. Gelatti¹⁶,¹⁷,¹⁸, S. Novello¹⁹, K. Stencel²⁰,²¹, N. Reguart²², J. Alatorre-Alexander²³, G.G-Y. Lai²⁴, N. Girard²⁵, C. Schulz²⁶, Y. Elamin²⁷, M. Nishio²⁸, H. Yu²9, B. Besse³⁰, Y. He³¹, R. Sopariwala³¹, M. Liu³¹, V. Wacheck³¹, F. Benedetti³¹, J. Heymach²⁷ 1Duke-NUS Medical School, Singapore/SG Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok/TH ³Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo/JP 4University of British Columbia, Vancouver/BC/CA ⁵Bc Cancer, Vancouver/BC/CA, 612 de Octubre Comprehensive Cancer Center, Madrid/ES /Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka/JP, ⁸Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju/KR, ⁹Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam/NL, Department of Medical Oncology, Başkent University, Adana/TR, 11 Royal Free London NHS Foundation Trust, London/GB Department of Respiratory Diseases University Hospitals KU Leuven, Leuven/BE, 13 Department of Medical Oncology 2, IRCCS, Reginal Elena National Cancer Institute, Rome/IT, Department of Thoracic Oncology Aichi Cancer Center, Nagoya/JP ¹⁵Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok/TH ⁶Department of Medical Oncology, Brazilian Group of Thoracic Oncology, Porto Alegre/BR Department of Medical Oncology, Oncoclínicas Institute, São Paulo/BR, Department of Medical Oncology, São Lucas Hospital, Porto Alegre/BR 19 Department of oncology, AOU san luigi, University of Turin, Orbassano/IT 20 Polish Mother's Memorial Hospital - Research Institute, Lodz/PL 21 Eugenia and Janusz Zeyland Greater Poland Centre of Pulmonology and Thoracic Surgery, Poznan/PL 22 Medical Oncology Department, Hospital Clínic Barcelona, Barcelona/ES 23 Clínica de Oncología Torácica, Health Pharma Professional Research, Mexico City/MX 24 Division of Medical Oncology, National Cancer Centre Singapore, Singapore/SG ²⁵Institut Curie, Paris/FR, 26Lung Cancer Center, University Hospital Regensburg, Regensburg/DE, 27The University of Texas MD Anderson Cancer Center, Houston/TX/USA, ²⁸Department of Thoracic Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo/JP 29 Memorial Sloan Kettering Cancer Center, New York/NY/USA ³⁰Paris Saclay University, Gustave Roussy, Villejuif/FR, 31 Taiho Oncology, Inc, Princeton/NJ/USA View abstract

ggilberto lopes@GlopesMd

1.9K impressions22 likes13 reposts2026-08-22

8ARROS-1preview only13.2K impressionsno primary data posted yet7 posts · 6 voices▾

From session previews

UUğur Özkerim@UOzkerim

4.2K impressions51 likes18 reposts2026-08-20

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

4.1K impressions33 likes9 reposts2026-08-19

ggilberto lopes@GlopesMd

1.9K impressions22 likes13 reposts2026-08-22

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Plenary Session
🔥ARROS-1: Zidesamtinib in TKI-naive Patients With Advanced/Metastatic ROS1+ NSCLC: Efficacy and Safety Data
🎙️ @alexdrilon
🔢PL03.06
☑️NCT05253794
🔗 https://t.co/mYsNwaWQUZ
@OncoAlert @Larvol @IASLC @ros1cancer https://t.co/KEwTHWEQ5A https://t.co/8rq3OuRfAi

1.6K impressions10 likes4 reposts2026-08-20

[Slide 1] PL03.06. Zidesamtinib in TKI-naive Patients with Advanced/Metastatic ROS1+ NSCLC: ARROS-1 Efficacy and Safety Data A. Drilon¹, A.J. de Langen², B. Besse³, A. Swalduz⁴, C.S. Baik⁵, E. Shum⁶, T. Yoshida⁷, G. Liu⁸, S.V. Liu9, J. Mazieres¹⁰, J.W. Neal¹¹, B.J. Solomon¹², D. Tan¹³, A.J. van der Wekken R. Ariyasu¹⁵, J.R. Bauman¹⁶, J-Y. Han¹⁷, D-W. Kim¹⁸, L. Landi¹⁹, J.J. Lin20, D.H. Owen²¹, H. Akamatsu R. Berardi²³, A. Calles²⁴, G. de Lima Lopes²⁵, E. Felip²⁶, M.C. Garassino²⁷, G-C. Chang²⁸, H. Hayashi²⁹, M. Johnson³⁰, S. Kao³¹, C-C. Lin³², C-C. Lin³³, K. Ninomiya³⁴, S. Park³⁵, G. Pasello³⁶, E. Pons-Tostivint³⁷, A.T. Shaw³⁸, R.A. Soo³⁹, S. Teranishi⁴⁰, S.N. Waqar⁴¹, M. Samant⁴², J. Shen⁴², V.A. Upadhyay⁴², B.C. Cho⁴³ Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York/NY/USA, ²Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Amsterdam/NL ³Institut Gustav Roussy, Villejuif/FR, Centre Léon Bérard, Lyon/FR, ⁵Fred Hutchinson Cancer Center, Seattle/WA/USA, ⁶Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York/NY/USA, National Cancer Center Hospital, Tokyo/JP ⁸Princess Margaret Hospital, Toronto/ON/CA, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C./DC/USA, Toulouse University Hospital, Université de Toulouse, Institut Claudius Rigaud, Toulouse/FR, Stanford Cancer Institute, Palo Alto/CA/USA, 12 Peter MacCallum Cancer Centre, Melbourne/AU, 13 National Cancer Centre Singapore, Singapore/SG, 14University of Groningen, University Medical Centre Groningen, Groningen/NL The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo/JP, ¹⁶Fox Chase Cancer Center, Philadelphia/PA/USA 17 National Cancer Center, Goyang/KR 18 Seoul National University Hospital, Seoul/KR, Istituti Fisioterapici Ospitalieri, Rome/IT 20 Mass General Brigham Cancer Institute, Boston/MA/USA, 21 The Ohio State University Comprehensive Cancer Center, Columbus/OH/USA 2Wakayama Medical University, Wakayama/JP 23 Università Politecnica delle Marche AOU delle Marche, Ancona/IT 24 Hospital General Universitario Gregorio Marañon, Madrid/ES, 25 Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami/FL/USA 26Vall d'Hebron Hospital Universitari, Barcelona/ES Knapp Center for Biomedical Discovery, The University of Chicago, Chicago/IL/USA 28 Chung Shan Medical University Hospital, Taichung/TW, 29 Kindai University, Osaka/JP, 30 Sarah Cannon Research Institute, Nashville/TN/USA, 31 Chris O'Brien Lifehouse, Sydney and The University of Sydney, Camperdown/AU 32 National Taiwan University Hospital, Taipei/TW 33 National Cheng Kung University Hospital and Tainan Hospital, Ministry of Health and Welfare, Tainan City/TW 34 Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama/JP 35 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR Stituto Oncologico Veneto IRCCS, Padua/IT 37 Centre Hospitalier Universitaire Nantes, Nantes/FR, ³⁸Dana-Farber Cancer Institute, Boston/MA/USA, 39 National University Hospital, Singapore/SG 40 Yokohama City University Medical Center, Yokohama/JP Washington University in St. Louis, St. Louis/MO/USA, Nuvalent Inc., Cambridge/MA/USA, ⁴³Yonsei Cancer Center, Seoul/KR View abstract @ of View biography

9ABBV-14808.9K impressions4.4K primary · 4.5K preview42 engagements5 posts · 5 voices▾

MMinhua Chu@chuminhua432

#WCLC2026 China Biopharma data

RemeGen — Updated Ph2 data for PD-1/VEGF bispecific RC148 (ABBV-1480, partnered w/ $ABBV ) + chemo in 1L NSCLC (OA14.04)

NCT06883630, AGA-negative, treatment-naive stage IIIB/C-IV NSCLC:
- Cohort 1 (squamous): RC148 + carbo/paclitaxel
- Cohort 2 (non-squamous): RC148 + carbo/pemetrexed Both randomized 10 vs 20 mg/kg, with maintenance

As of Mar 22, 2026 (n=61 sq

2.6K impressions19 likes5 reposts2026-08-21

[Slide 1] Table 1. Clinical Efficacy Data. Cohort 1 (sq-NSCLC) Cohort 2 (nsq-NSCLC) RC148 (10 mg/kg) + RC148 (20 mg/kg) + RC148 (10 mg/kg) + RC148 (20 mg/kg) + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Carboplatin + Pemetrexed Carboplatin + Pemetrexed (N=30) (N=31) (N=30) (N=30) Median follow-up, months 8.7 9.1 27/30 22/28 22/29 11/28 ORR*, n/N (%; 95% CI) (90.0; 73.5-97.9) (78.6; 59.0-91.7) (75.9; 56.5-89.7) (39.3; 21.5-59.4) DoR Median (95% CI), NR 7.2 (4.1-NR) NR NR months 6-month DoR rate, % 66.5 (41.9-82.6) /8 64.6 (37.4-82.4) /9 80.2 (55.4,92.1) /8 90.0 (47.3, 98.5) /8 (95% CI)/number at risk 9-month DoR rate, % NR 46.0 (18.2, 70.1) /2 80.2 (55.4, 92.1) /3 90.0 (47.3, 98.5) /4 (95% CI)/number at risk PFS Median (95% CI), 10.8 (6.9-NR) 8.5 (5.4-NR) NR 10.4 (6.7-NR) months 6-month PFS rate, % 80.0 (58.4-91.1) /20 60.5 (38.7-76.6) /14 82.8 (63.4-92.4) /24 73.2 (51.8-86.2) /18 (95% CI)/number at risk 9-month PFS rate, % 67.8 (45.7-82.4) /6 42.5 (20.2-63.3) /4 68.0 (47.3-82.0) /7 57.4 (34.4-74.9) /5 (95% CI)/number at risk OS Median (95% CI), NR NR NR NR months 9-month OS rate, % 87.0 (64.1-95.7) /12 79.0 (58.8-90.1) /10 90.0 (72.1-96.7) /15 85.4 (65.4-94.3) /15 (95% CI)/number at risk Subgroup Analysis PD-L1 TPS <1% 14/15 7/9 10/14 4/16 (ORR*, n/N (%; 95% (93.3; 68.1-99.8) (77.8; 40.0-97.2) (71.4; 41.9-91.6) (25.0; 7.3-52.4) CI)) PD-L1 TPS >1% 12/14 13/16 10/13 7/11 (ORR*, n/N (%; 95% (85.7; 57.2-98.2) (81.3; 54.4-96.0) (76.9; 46.2-95.0) (63.6; 30.8-89.1) CI)) *Analyzed in patients with ≥1 post-baseline tumor assessment. NR=not reached.

MMichel Doepke@doepke_michel

$ABBV to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline. Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline NSCLC setting will be presented via an oral presentation. $BNTX $PFE $BMY https://t.co/AvTIg1CYaq

1.7K impressions8 likes0 reposts2026-08-21

RRecon Bull@ReconBull

AbbVie to present new data from its ABBV-1480 PD-1/VEGF bispecific antibody for frontline non-small cell lung cancer at the 2026 World Conference on Lung Cancer $ABBV

89 impressions0 likes0 reposts2026-08-21

From session previews

KKazuo@kayaba_mo

2.9K impressions22 likes2 reposts2026-08-23

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Oral Session
🔥RC148 (ABBV-1480, PD-1/VEGF Bispecific Antibody) Plus Chemotherapy in First-Line Locally Advanced or Metastatic NSCLC
🎙️Dr. Li Zhang
🔢OA14.03
🎯ORR 90.0% (Squamous) and 75.9% (Non-Squamous)
🎯PD-L1-Negative ORR 93.3%
☑️NCT06883630
🔗 https://t.co/xZaNz9voMP
@OncoAlert @Larvol @IASLC

1.6K impressions11 likes3 reposts2026-08-24

[Slide 1] OA14.03. RC148 (ABBV-1480, PD-1/VEGF Bispecific Antibody) Plus Chemotherapy in First-Line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Table 1. Clinical Efficacy Data. L. Zhang¹, Y. Zhao¹, Y. Fan², Y. Luo³, F. Ning⁴, Q. Wang⁵, Y. Wang⁵, D. Lv⁶, Q. Cohort 1 (sq-NSCLC) Cohort 2 (nsq-NSCLC) Wen⁷, M. Sun7, D. Huang⁸, Y. Zhao⁹, D. Lin¹⁰, B. Li¹¹, W. Zheng¹², Y. Yu¹³, Y. Ji¹⁴, B. Chen¹⁵ J. Shi¹⁶, Q. Yu17, W. Jiang¹⁷, X. Lu¹⁸, G. Ma¹⁸, M.M. Shi¹⁸, J. Fang¹⁹ RC148 (10 mg/kg) + RC148 (20 mg/kg) + RC148 (10 mg/kg) + RC148 (20 mg/kg) + Sun Yat-sen University Cancer Center, Guangzhou/CN ²Zhejiang Cancer Hospital, Carboplatin + Paclitaxel Carboplatin + Paclitaxel Carboplatin + Pemetrexed Carboplatin + Pemetrexed Hangzhou/CN ³Hunan Cancer Hospital, Changsha/CN 4Binzhou Medical University (N=30) (N=31) (N=30) (N=30) Hospital, Binzhou/CN Nanyang Second General Hospital, Nanyang/CN ⁶Taizhou Hospital Median follow-up, months 8.7 9.1 of Zhejiang Province of Wenzhou Medical University, Taizhou/CN Central Hospital 27/30 22/28 22/29 11/28 Affiliated to Shandong First Medical University, Jinan/CN, ⁸Tianjin Medical University Cancer ORR*, n/N (%; 95% CI) (90.0; 73.5-97.9) (78.6; 59.0-91.7) (75.9; 56.5-89.7) (39.3; 21.5-59.4) Institute &Hospital, Tianjin/CN, Henan Cancer Hospital, Zhengzhou/CN 10 Jiangmen Central DoR Hospital, Jiangmen/CN, ¹¹The Second Affiliated Hospital of Guilin Medical University, Guilin/CN Shengjing Hospital of China Medical University, Shenyang/CN 13 Harbin Medical Median (95% CI), NR 7.2 (4.1-NR) NR NR University Cancer Hospital, Harbin/CN, ¹⁴The First Affiliated Hospital of Henan Medical months University, Xinxiang/CN, ¹⁵The Affiliated Hospital of Xuzhou Medical University, Xuzhou/CN 6-month DoR rate, % 66.5 (41.9-82.6) /8 64.6 (37.4-82.4) /9 80.2 (55.4, 92.1) /8 90.0 (47.3, 98.5) /8 16 Linyi Cancer Hospital, Linyi/CN, 17 Affiliated Cancer Hospital of Guangxi Medical (95% CI)/number at risk University, Nanning/CN, ⁸RemeGen Co., Ltd., Yantai/CN 19 School of Life Science and 9-month DoR rate, % NR Technology, Tongji University, Shanghai/CN 12:52 PM - 1:02 PM 10m 46.0 (18.2, 70.1) /2 80.2 (55.4, 92.1) /3 90.0 (47.3, 98.5) /4 (95% CI)/number at risk View abstract PFS Introduction: RC148 (ABBV-1480) is a novel bispecific antibody targeting PD-1 and VEGF. Previous data showed encouraging anti-tumor activity with a manageable safety profile for Median (95% CI), 10.8 (6.9-NR) 8.5 (5.4-NR) NR 10.4 (6.7-NR) RC148 monotherapy and combined with docetaxel in patients with NSCLC (ESMO IO months Congress, 2025). We report here the first-line RC148 plus platinum-based chemotherapy in 6-month PFS rate, % patients with NSCLC (NCT06883630). 80.0 (58.4-91.1) /20 60.5 (38.7-76.6) /14 82.8 (63.4-92.4) /24 73.2 (51.8-86.2) /18 (95% CI)/number at risk Methods: Treatment-naive, unresectable stage IIIB/C or stage IV NSCLC without actionable genomic alterations (AGA) were enrolled. Patients with squamous NSCLC (sq-NSCLC) were 9-month PFS rate, % 67.8 (45.7-82.4) /6 42.5 (20.2-63.3) /4 68.0 (47.3-82.0) /7 57.4 (34.4-74.9) /5 randomized 1:1 to receive RC148 (10 or 20 mg/kg) plus carboplatin/paclitaxel (Cohort 1), (95% CI)/number at risk followed by maintenance treatment; patients with non-squamous NSCLC (nsq-NSCLC) were os randomized 1:1 to receive RC148 (10 or 20 mg/kg) plus carboplatin/pemetrexed (Cohort 2), also with maintenance. Tumor response was assessed per RECIST v1.1 by the Median (95% CI), NR NR NR NR investigators. The primary endpoint was objective response rate (ORR); secondary months endpoints included disease control rate (DCR), duration of response (DoR), progression- 9-month os rate, % free survival (PFS), overall survival (OS), and safety. 87.0 (64.1-95.7) /12 79.0 (58.8-90.1) /10 90.0 (72.1-96.7) /15 85.4 (65.4-94.3) /15 (95% CI)/number at risk Results: By data cutoff (March 22, 2026), 61 patients with sq-NSCLC and 60 nsq-NSCLC were enrolled. In Cohort 1, RC148 10 mg/kg achieved an ORR of 90.0% (95% Cl: 73.5-97.9), Subgroup Analysis with PD-L1-negative (TPS <1%) ORR of 93.3%-exceeding AK112's 71.2% in HARMONi-6. PD-L1 TPS <1% Median PFS was 10.8 months. In Cohort 2, RC148 10 mg/kg yielded an ORR of 75.9%, with 14/15 7/9 10/14 4/16 (ORR*, n/N (%; 95% PD-L1-negative ORR of 71.4%. No grade ≥3 hemorrhages occurred at 10 mg/kg. The most (93.3; 68.1-99.8) (77.8; 40.0-97.2) (71.4; 41.9-91.6) (25.0; 7.3-52.4) common treatment-related adverse events (TRAEs) were white blood cell count decreased, CI)) neutrophil count decreased, anemia, and platelet count decreased for both cohorts. Grade PD-L1 TPS ≥1% 12/14 13/16 10/13 7/11 ≥3 TRAEs occurred in 66.7% patients (10 mg group) and 71.0% (20 mg group) in Cohort 1; (ORR*, n/N (%; 95% (85.7; 57.2-98.2) (81.3; 54.4-96.0) (76.9; 46.2-95.0) (63.6; 30.8-89.1) 70.0% and 76.7% in Cohort 2. CI)) Conclusions: RC148 plus chemotherapy demonstrated promising efficacy with a *Analyzed in patients with ≥1 post-baseline tumor assessment. NR=not reached. manageable safety profile in first-line treatment of NSCLC. The 10 mg/kg dose, with superior outcomes across histology and high activity irrespective of PD-L1 status, is the recommended phase 3 dose in first-line NSCLC. Pivotal phase 3 studies have been initiated or planned both in China and globally.

10NAUTIKA1preview only7.4K impressionsno primary data posted yet2 posts · 1 voices▾

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Oral Session
🔥NAUTIKA1: Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC
🎙️ @ChaftJamie
🔢OA04.04
🎯MPR 42%, pCR 16% (n=19)
🎯Radiographic ORR 55%
🎯No Treatment Discontinuations Due to AEs
☑️NCT04302025
🔗 https://t.co/rN1vqVmvgD
@OncoAlert @Larvol @IASLC @KRASKickers

5.4K impressions13 likes8 reposts2026-08-21

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Mini Oral Session
🔥NAUTIKA1: Primary Analysis of Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK+ NSCLC
🎙️Dr. Jay M. Lee
🔢MO06.01
🎯R0 Resection in 95%
🎯MPR 55.8%, pCR 18.6% (n=43)
🎯2-Yr EFS 94%, DFS 96%, OS 97% (n=48)
☑️NCT04302025
🔗 https://t.co/6rnqfaalhV @OncoAlert @Larvol @IASLC

2K impressions11 likes5 reposts2026-08-27

[Slide 1] MO06.01. NAUTIKA1: Primary Analysis of Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK+ NSCLC J.M. Lee¹, A. Cummings², N. Florez³, N. Mohindra⁴, D. Wigle⁵, J. Lin⁶, C.A. Shu⁷, A. Saltos⁸, E. Shum⁹, M.V. Negrao¹⁰, T. Patil¹, L. Sholl¹², A. Saqi7, E. Kadel¹³, B. Ding¹³, C. Ngiam I. Bara¹³, J. Chaft University of California, Los Angeles/CA/USA, David Geffen School of Medicine at the University of California, Los Angeles/CA/USA, Dana-Farber Cancer Institute-Harvard Medical School, Boston/MA/USA ⁴Feinberg School of Medicine Northwestern University, Chicago/IL/USA Mayo Clinic, Rochester/MN/USA, Univeristy of Michigan Medical School, Ann Arbor/MI/USA, Columbia University Medical Center, New York/NY/USA, Moffitt Cancer Center, Tampa/FL/USA NYU Langone Perlmutter Cancer Center, New York/NY/USA, 10MD Anderson Cancer Center, Houston/TX/USA, Univeristy of Colorado Cancer Center, Aurora/CO/USA, Brigham and Women's Hospital, Boston/MA/USA 13 Genentech, Inc., South San Francisco/CA/USA, 14 MSKCC and Weill Cornell Medical College, New York/NY/USA L 3:32 PM - 3:37 PM 5m View abstract Jo View biography Introduction: Alectinib is a globally approved adjuvant treatment for patients with resected, stage IB-IIIB (AJCC 8th edition), ALK + non-small cell lung cancer (NSCLC). However, limited data exist for neoadjuvant alectinib in this population. NAUTIKA1 (NCT04302025) is a Phase II umbrella study of multiple therapies in biomarker-selected patients with resectable NSCLC. Preliminary data from the ALK + cohort (n=33) were previously presented. We report the primary analysis of pathological, neoadjuvant clinical and surgical findings, alongside post-neoadjuvant outcomes in the full ALK + cohort (N=48). Methods: Eligible patients were ≥18 years old with stage IB-IIIB (T3N2 only) ALK + NSCLC and ECOG PS 0/1. Patients received neoadjuvant alectinib (600mg, twice daily [BID]) for 8 weeks followed by surgery, optional platinum-based chemotherapy (≤4 cycles), then adjuvant alectinib (600mg BID) for 2 years. Primary endpoint was major pathologic response (MPR; ≤ ≤10% residual viable tumour cells). Secondary endpoints included pathologic complete response (pCR), radiographic response, downstaging, event-free survival (EFS), disease-free survival (DFS), overall survival (OS), neoadjuvant ctDNA clearance status and safety. Results: At data snapshot (09 February 2026), enrolment was completed (N=48; Table). MPR was achieved in 24/43 (55.8%) patients and pCR in 8/43 (18.6%) (Figure). Radiographic objective response was observed in 27/45 (60.0%) patients. Clinical downstaging was observed in 17/45 (37.8%) patients and 14/45 (31.1%) were downstaged to ypN0. With a median follow-up of 20.8 months, 2-year EFS rate was 94%, 2-year DFS rate was 96%, and 2-year OS rate was 97%. R0 resection occurred in 40/42 (95%) patients. Co- mutation and ctDNA data are being assessed. Neoadjuvant alectinib was well tolerated with no new safety signals. Conclusions: This primary analysis from NAUTIKA1 demonstrated clinically meaningful MPR, pCR and objective response rates with no new safety signals. Neoadjuvant alectinib is a promising treatment that can be added as a perioperative approach for resectable, stage Weighted % viable tumour regression in the pathological response analysis population (n=40) 0 20 Percentage 2 40 60 80 90% (MPR) 100 MFR Non MFR POR For patients who did not undergo primary tumour RO resection, weighted percentage of tumour regression values were treated as missing and excluded from the graph. MPR, major pathologic response primary endpoint): pCR, pathological complete response. IB-IIIB ALK + NSCLC.

11DeLLphi-3095.4K impressions3.1K primary · 2.2K preview6 engagements2 posts · 2 voices▾

LLaura Alder, MD@LauraAlderMD

🚨 Who's ready for SCLC updates at #WCLC26?! 🫁
1️⃣ Dr J͟o͟n͟a͟t͟h͟a͟n͟ ͟G͟o͟l͟d͟m͟a͟n͟ presents DeLLphi-309: randomized Phase 2 of tarlatamab extended-interval dosing in SCLC. 💉 Less-frequent dosing could ease treatment burden and "time toxicity," keeping efficacy while giving patients back more days off therapy.
2️⃣ Dr A͟l͟b͟e͟r͟t͟o͟ ͟C͟h͟i͟a͟p͟p͟o͟r͟i͟ on LB2102: a dnTGFBR2-armored

3.1K impressions4 likes1 reposts2026-08-24

[Slide 1] OA05. From Discovery to Practice in SCLC: Redefining Standards of Care and the Next Generation of Targeted Therapies - Sunday, September 13, 2026 at 4:45 PM KST / UTC +9 1h 15m Room 103, Grand Ballroom, 1F Description: This oral session presents the highest-rated abstracts in small cell lung cancer and neuroendocrine tumors, with a focus on practice-changing Phase 3 trials and novel targeted therapies including DLL3-directed bispecifics and CAR-T cell therapy, and B7-H3-targeted antibody-drug conjugates. Presentations in this session Chair Sofia Baka, Medical Oncologist MD, MSc, PhD, MEDICAL ONCOLOGY/CLINICAL TRIAL DEPARTMENT, INTERBALKAN MEDICAL CENTER, THESSALONIKI, Greece 4:45 PM- 4:46 PM 1m View biography Chair Rosalyn Juergens, MD PhD, Oncology, McMaster University, Hamilton, ON, Canada 4:46 PM 4:47 PM 1m jo View biography OA05.01. Tarlatamab Extended-Interval Dosing Regimens in Patients With SCLC: The Randomized Phase 2 DeLLphi-309 Study J. Goldman¹, S.I. Rothschild²,³, I. Korantzis⁴, B.C. Cho⁵, S. Arulananda⁶, 0. Yazici7, M. Besiroglu8, A. Lugini9, S.Y. Lee¹⁰, L. Paz-Ares¹¹, M. Wang¹², D. Huang¹³, G. Mountzios¹⁴, H. Yokouchi¹⁵, T. Larson¹⁶, E. Selfridge¹ M. Minocha¹⁷, E. Benjamin¹⁷, S. Huang¹⁷, P. Rocha¹⁸ University of California Los Angeles, Los Angeles/CA/USA 2Kantonsspital Baden, Baden/CH 3University of Basel, Basel/CH ⁴European Interbalkan Medical Center, Thessaloniki/GR, ⁵Severance Hospital Yonsei University Health System, Seoul/KR, Monash Health, Clayton/AU Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi, Ankara/TR, ⁸Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul/TR Azienda Ospedaliera San Giovanni Addolorata, Rome/IT, 10Kyungpook National University Chilgok Hospital, Daegu/KR, Hospital Universitario 12 de Octubre, Madrid/ES, Peking Union Medical College Hospital, Beijing/CN, 13 Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN, Henry Dunant Hospital Center, Athens/GR, National Hospital Organization Hokkaido Cancer Center, Hokkaido/JP, 6Health Partners Cancer Center at Regions Hospital, St. Paul/MN/USA 17 Amgen Inc., Thousand Oaks/CA/USA, 18 University Hospital Vall Hebron, Barcelona/ES 4:47 PM- 4:57 PM 10m View abstract Jo View biography OA05.02. Phase 1 Study of LB2102, a dnTGFBR2-armored DLL3-targeted Autologous CAR-T Cell Therapy, in Subjects With Relapsed or Refractory SCLC or LCNEC A. Chiappori¹, Z. Hao2, B. Creelan¹, R. Munker2, P. Schwarzenberger³, N. Patel³, S. Vahora3, C. Davis3, C. Wang3, J. Zhang3, L. Xin3, J. Zhu³, Y. He³, A. Schoenfeld⁴, J. Sands5 Moffitt Cancer Center, Tampa/FL/USA 2Markey Cancer Center, University of Kentucky, Lexington/KY/USA Legend Biotech USA Inc, Somerset/NJ/USA 4Memorial Sloan Kettering Cancer Center, New York City/NY/USA 5Dana Farber Cancer Institute, Boston/MA/USA 4:57 PM- 5:07 PM 10m View abstract of View biography OA05.03. Epigenetic Dysregulation Permits E2F1 Activation-Mediated Neuroendocrine Transformation inEGFR-Mutant Lung Adenocarcinoma Z. Xia¹, J. Li¹, Q. Sun¹, R. Yin1,2,3 1 Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing/CN 2Department of Thoracic Surgery, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing/CN 3Collaborative Innovation Center for Cancer Personalized Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, Nanjing/CN 5:07 PM- 5:17 PM 10m View abstract JO View biography OA05.04. Discussant H. Akamatsu; Nagoya City University, Nagoya, JAPAN. L 5:17 PM- 5:27 PM 10m of View biography

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Oral Session
🔥DeLLphi-309: Tarlatamab Extended-Interval Dosing Regimens in Patients With SCLC: The Randomized Phase 2 Study
🎙️Dr. Jonathan W. Goldman
🔢OA05.01
☑️NCT06745323
🔗 https://t.co/9slGIchsnX
@OncoAlert @Larvol @IASLC https://t.co/eL7Vx1UpqQ

2.2K impressions15 likes7 reposts2026-08-21

[Slide 1] OA05.01. Tarlatamab Extended-Interval Dosing Regimens in Patients With SCLC: The Randomized Phase 2 DeLLphi-309 Study J. Goldman¹, S.I. Rothschild²,³, I. Korantzis⁴, B.C. Cho⁵, S. Arulananda⁶, 0. Yazici⁷, M. Besiroglu8, A. Lugini9, S.Y. Lee¹⁰, L. Paz-Ares¹¹, M. Wang¹², D. Huang 13 G. Mountzios H. Yokouchi¹⁵, T. Larson¹⁶, E. Selfridge¹⁷ M. Minocha¹⁷, E. Benjamin S. Huang¹⁷, P. Rocha¹⁸ University of California Los Angeles, Los Angeles/CA/USA, 2 Kantonsspital Baden, Baden/CH, 3University of Basel, Basel/CH, ⁴European Interbalkan Medical Center, Thessaloniki/GR, ⁵Severance Hospital Yonsei University Health System, Seoul/KR, ⁶Monash Health, Clayton/AU, Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi, Ankara/TR, 8 Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul/TR Azienda Ospedaliera San Giovanni Addolorata, Rome/IT, ¹⁰Kyungpook National University Chilgok Hospital, Daegu/KR, 11 Hospital Universitario 12 de Octubre, Madrid/ES, -Peking Union Medical College Hospital, Beijing/CN, 13 Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN, 14 Henry Dunant Hospital Center, Athens/GR, ¹⁵National Hospital Organization Hokkaido Cancer Center, Hokkaido/JP, 16 Health Partners Cancer Center at Regions Hospital, St. Paul/MN/USA, 17 Amgen Inc., Thousand Oaks/CA/USA , 18 University Hospital Vall Hebron, Barcelona/ES , 4:47 PM - 4:57 PM - 10m View abstract @ of View biography

12HARMONi5.3K impressions3.4K primary · 2K preview42 engagements5 posts · 5 voices▾

DDr. Antonio Calles 🫁🚭@Tony_Calles

Updated overall survival data from the #HARMONi clinical trial on ivonescimab will be presented on September 15th at the @IASLC World Congress on Lung Cancer (#WCLC 2026) in Seoul #LCSM https://t.co/gZbFGP34GD

2.1K impressions18 likes5 reposts2026-08-25

ggilberto lopes@GlopesMd

1. OA14.05 — HARMONi updated OS. Ivonescimab + chemo after a 3rd-gen EGFR TKI: PFS 6.8 vs 4.4 mo (HR 0.52), OS HR 0.76 in the July analysis. PDUFA is Nov 14. The highest-stakes number of the meeting, presented eight weeks before the FDA decides. @iaslc #wclc26 @SMMT_TX #LCSM https://t.co/MbLtwgCYYO

542 impressions7 likes1 reposts2026-08-27

[Slide 1] - 4 T Cell Tumor Cell Anti- Anti-Angiogenesis VEGF

BBanancial@Banancial

$SMMT — Ivonescimab delivers a major win for lung cancer patients, cutting progression risk by 48%. We peeled the primary analysis from the global Phase 3 HARMONi trial, now published in The Lancet Oncology. SMMT's drug plus chemo extended median progression-free survival to 6.8 months versus just 4.4 months for placebo, with a Hazard Ratio of 0.52. This is the first peer-reviewed data, addin

498 impressions1 likes0 reposts2026-08-25

EEGFR Positive Lung Cancer UK@EgfrUk

We’re starting to see some important #lungcancer data appearing ahead of #WCLC26

A big result to look out for relevant to our EGFR+ community is the Phase 3 HARMONi trial.

It looked at people with advanced EGFR+ whose cancer had progressed after a 3rd-generation EGFR-targeted treatment such as osimertinib.

Ivonescimab plus chemotherapy improved median progression-free survival compared with che

169 impressions1 likes1 reposts2026-08-27

[Slide 1] egfrpositive.org.uk EGFR UK Together in hope A major new treatment result for EGFR+ lung cancer Phase 3 HARMONi trial in advanced EGFR+ lung cancer after progression on third-generation EGFR-targeted treatment.

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Oral Session
🔥HARMONi: Ivonescimab-Chemo vs Placebo-Chemo in EGFR-TKI-Resistant, EGFR-Mutated NSCLC: Updated Overall Survival Analysis
🎙️ @APassaroMD
🔢OA14.04
🎯mOS 17.5 vs 14.0m in Western Cohort (HR 0.76)
🎯ITT mOS 16.8 vs 14.0mo (HR 0.76)
🎯No New Safety Signals
☑️NCT06396065
🔗 https://t.co/xZaNz9voMP
@OncoAlert @Larvol @IASLC @EGFRResisters

2K impressions18 likes6 reposts2026-08-24

[Slide 1] OA14.04. Ivonescimab-Chemo vs Placebo-Chemo in EGFR-TKI-Resistant, EGFR- Mutated NSCLC (HARMONi): Updated Overall Survival Analysis A. Passaro¹, J. Goldman², J. Laskin³, D. Rodriguez-Abreu⁴, A. Calles⁵, L. Bazhenova⁶, G. Lo Russo⁷, N. Leighl⁸, F. Cappuzzo⁹, N. Girard¹⁰, S. Popat¹¹,¹², W. Fang¹³, Y. Luo¹⁴, R. Yang¹⁵, H. West¹⁶, I. Lal¹⁶, J. Li¹⁶, L. Zhang¹³, X. Le¹⁷ European Institute of Oncology IRCCS, Milan/IT UCLA Health, Los Angeles/CA/USA ,British Columbia Cancer Research Institute, University of British Columbia, Vancouver/BC/CA, 4Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria/ES ⁵Hospital General Universitario Gregorio Marañon, Madrid/ES ⁶Moores Cancer Center, UC San Diego, San Diego/CA/USA, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan/IT ⁸UHN Princess Margaret Cancer Centre University of Toronto, Toronto/ON/CA ,⁹Regina Elena National Cancer Institute, Rome/IT, ¹⁰Institut Curie, Paris/FR, 11 Royal Marsden Hospital, London/GB Institute of Cancer Research, London/GB ¹³Sun Yat-sen University Cancer Center, Guangzhou/CN, Hunan Cancer Hospital, Changsha/CN, ⁵The Second Department of Medical Oncology, Yunnan Cancer Hospital, Kunming/CN, ¹⁶summit Therapeutics Inc., Palo Alto/CA/USA ¹⁷The University of Texas MD Anderson Cancer Center, Houston/TX/USA 4 1:02 PM - 1:12 PM 10m View abstract JO View biography Introduction: Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody in global development and approved for 2 NSCLC indications in China. HARMONi is the first global phase 3 study evaluating ivonescimab plus chemotherapy in patients with EGFR-mutated NSCLC post third-generation EGFR TKIs, enrolling patients from North America/Europe (Western cohort) and in China (Asian cohort). Primary analyses from HARMONi demonstrated a statistically significant improvement in progression-free survival (PFS) with ivonescimab-chemotherapy versus placebo-chemotherapy and favorable overall survival (OS) outcomes (data cutoff: April 2025; median follow-up 29.7 months [Western cohort, 9.2 months]; HR 0.79 [95% CI, 0.62-1.01]), and a tolerable safety profile. Here, we present a long-term OS analysis with extended follow-up for patients in the Western cohort, with approximately 2 years median follow-up. Methods: HARMONi is a global, randomized, double-blinded, phase 3 study evaluating the efficacy and safety of ivonescimab-chemotherapy versus placebo-chemotherapy for patients with EGFR-mutated NSCLC whose cancer progressed on a third-generation EGFR TKI. Eligible patients were randomly assigned (1:1) to receive ivonescimab (20 mg/kg) or placebo plus pemetrexed and carboplatin every 3 weeks for 4 cycles, followed by maintenance therapy. Randomization was stratified by presence/absence of brain metastases and geographic region. Dual primary endpoints were PFS (by independent review committee) and OS. Secondary endpoints included safety. This updated analysis was based on an extended follow-up of patients in the Western cohort (data cutoff: June 2026); the data cutoff for the Asian cohort aligned with the previous analysis (April 2025). An OS sweep was performed, with an additional 33 deaths and a total of 109 deaths reported among the 165 patients in the Western cohort. Results: From January 2022-October 2024, 438 patients were randomized (219 per arm); 165 patients in the Western cohort and 273 patients in the Asian cohort. In the intention-to- treat (ITT) population, the median age was 62 years, 257 (58.7%) patients were female, and 108 (24.7%) had brain metastases at baseline. At this data cutoff, the median follow-up was 29.9 months (Western cohort: 23.2 months; Asian cohort: 32.7 months). The median OS in the ITT population was 16.8 months versus 14.0 months in the ivonescimab-chemotherapy versus placebo-chemotherapy arms (HR 0.76 [95% CI 0.61-0.95]; nominal P = 0.0151); in the Western cohort, median OS was 17.5 months versus 14.0 months (HR 0.76 [95% CI 0.52- 1.10]). In the safety population, the safety profile remained generally consistent with the previous analysis. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 112 (51.4%) versus 95 (43.6%) patients treated with ivonescimab-chemotherapy versus placebo- chemotherapy (grade ≥3 serious TRAEs occurred in 51 (23.4%) and 31 (14.2%) patients, respectively). TRAEs led to discontinuation of ivonescimab or placebo in 20 (9.2%) versus 14 (6.4%) patients, and death in 4 (1.8%) versus 6 (2.8%) patients. Conclusions: This updated OS analysis conducted with extended follow-up in the Western cohort showed a sustained OS benefit with ivonescimab-chemotherapy in the ITT population. The OS improvements were durable and consistent across geographic regions, with no new safety signals.

13DESTINY-Lung04preview only5.2K impressionsno primary data posted yet2 posts · 2 voices▾

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Plenary Session
🔥DESTINY-Lung04: First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-Mutant NSCLC: Primary Results
🎙️ @JuliaRotow
🔢PL03.08
🎯T-DXd Showed Statistically Significant and Clinically Meaningful PFS Improvement vs SOC (Chemo+Pembrolizumab) as First-Line Therapy
☑️NCT05048797
🔗 https://t.co/gAahGHJGeA
@OncoAlert @Larvol @IASLC

5K impressions47 likes20 reposts2026-08-21

[Slide 1] PL03.08. First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2 -Mutant NSCLC: DESTINY-Lung04 Primary Results J. Rotow¹, I. Okamoto², K. Goto³, M-J. Ahn⁴, P. Cheema⁵, J. Mazieres⁶, S. Novello⁷, D. Lv⁸, Y. Zhang⁹, A. Passaro¹⁰, E. Nadal¹¹, H-W. Ko¹², H-Y. Tu¹³, N. Menon E. Bria¹⁵, J. Chaft¹⁶, M. Hochmair¹⁷, M. Chaudhari¹⁸, A. van der Wekken¹⁹, P. Tomasini²⁰, S.K. Padda²¹, W.N. William Jr²², A. Vishweswaramurthy23, Y-T. Chang²⁴, E. Schreffler²⁴, B. Li²⁴, Y-L. Wu¹³ Dana-Farber Cancer Institute, Boston/MA/USA, Kyushu University Hospital, Fukuoka/JP 3 National Cancer Center Hospital East, Kashiwa/JP, 4Samsung Medical Center, Sungkyunkwan University, Seoul/KR 5University of Toronto, William Osler Health System, Brampton/ON/CA, 6 CHU de Toulouse, Université de Toulouse, Toulouse/FR, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, University of Turin, Turin/IT ,⁸Taizhou Hospital of Zhejiang Province, Taizhou/CN, ⁹Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, Hunan/CN, ¹⁰European Institute of Oncology IRCCS, Milan/IT 11 Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona/ES, 12 Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan City/TW, 13 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou/CN, 14 Tata Memorial Hospital, Mumbai, Maharashtra/IN, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome/IT, Memorial Sloan Kettering Cancer Center, New York City/NY/USA, 17 Klinik Floridsdorf, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Vienna/AT, ¹⁸HCG Manavata Cancer Centre, Mumbai Naka, Nashik/IN 19 University of Groningen, University Medical Center Groningen, Groningen/NL ²⁰Aix-Marseille University, CRCM, INSERM, CNRS, Assistance Publique- Hôpitaux de Marseille (APHM), Marseille/FR, 21 Fox Chase Cancer Center, Temple Health, Philadelphia/PA/USA, 22 Groupo Oncoclínicas, São Paulo/BR, 23 AstraZeneca, Bangalore/IN 24 AstraZeneca, Gaithersburg/MD/USA View abstract @1 Jo View biography

DDr. Estela Rodriguez@Latinamd

#WCLC26 When there is so much to cover that you have to add a 2nd Presidential Symposium. Here is my take on why these abstracts matter:

▶️ PL03.01: ADAURA 8-year OS landmark update of adjuvant #osimertinib
Looking at durability of benefit years after completing osimertinib and who could potentially benefit from continuation of therapy.

▶️ PL03.03: PAPILLON — More data on benefit of #amivantama

193 impressions1 likes0 reposts2026-08-27

[Slide 1] WCLC 2026 WCLC 2026 SEOUL PRESIDENTIAL SYMPOSIUM 2 MONDAY, SEPTEMBER 14 PL03.01 ADAURA 8-year overall survival update of adjuvant osimertinib in resected EGFR-mutated NSCLC. PL03.03 PAPILLON Amivantamab plus chemotherapy in EGFR exon 20 insertion NSCLC. PL03.04 REZILIENT 3 Zipalertinib plus chemotherapy in EGFR exon 20 insertion NSCLC. NEXT-GENERATION PL03.06 ARROS-1 TARGETED THERAPIES. TRANSFORMING OUTCOMES Zidesamtinib in treatment-naive ROS1-positive NSCLC. ACROSS LUNG CANCER. PL03.08 DESTINY-Lung04 #WCLC26 Trastuzumab deruxtecan in first-line HER2-mutant metastatic NSCLC. IASLC INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

14MDT-BRIDGEpreview only4.3K impressionsno primary data posted yet1 posts · 1 voices▾

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Oral Session
🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC
🎙️ @MartinReck2
🔢OA04.02
🎯Resection Rate 74.6%; pCR 27.3% and 12-Mo EFS 90.1% in Resectable Cohort
☑️NCT05925530
🔗 https://t.co/rN1vqVmvgD
@OncoAlert @Larvol @IASLC

4.3K impressions33 likes11 reposts2026-08-21

[Slide 1] OA04.02. Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC: MDT-BRIDGE Primary Analysis Resectable Borderline resectable All patients at baseline at baseline M. Reck¹, E. Nadal², C.M. Gay³, N. Girard⁴, A.R. Filippi⁵, L. Martin⁶, C. Petersen⁷, (N=142) (n=92) (n=50) D.A. Cairns⁸, M. Majem Tarruella⁹, A. Ardizzoni¹⁰, R. Alvarez Alvarez¹¹, A. Robinson B. Roch¹ A. Boyer¹⁴, I. Attili¹⁵, L. Li¹⁶, I. Diaz Perez¹⁷, M. Giaj MDT reassessment, n Resectable 121 83 38 Levra¹⁸, N. Georgoulia¹ J. Spicer¹⁹ Unresectable 21 9 12 Lung Clinic Großhansdorf, Airway Research Center North, German Center for Lung Resection rate, n (%; 95% CI) 106 (74.6; 66.7-81.6) 75 (81.5; 72.1-88.9) 31 (62.0; 47.2-75.3) Research, Grosshansdorf/DE 2Institut Català d'Oncologia - ICO Hospitalet, IDIBELL, Barcelona/ES 3University of Texas MD Anderson Cancer Center, Houston/TX/USA, 4Institut Completed surgery, n (%) 104 (98.1) 74 (98.7) 30 (96.8) du Thorax Curie Montsouris, Institut Curie/UVSQ, Paris/FR, Radiation Oncology Received CRT, n (%) 25 (17.6) 13 (14.1) 12 (24.0) Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan/IT University of Virginia, Charlottesville/VA/USA University Medical Center Hamburg-Eppendorf, No local treatment, n (%) 11 (7.7) 4 (4.3) 7 (14.0) Hamburg/DE Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical RO resection outcomes, n (%; 95% CI) 102 (96.2; 90.6-99.0) 72 (96.0; 88.8-99.2) 30 (96.8; 83.3-99.9) Trials Research, University of Leeds, Leeds/GB Hospital de La Santa Creu I Sant Pau, Resectable at MDT Unresectable at MDT Barcelona/ES, ¹⁰IRCCS Azienda Ospedaliero-Universitaria di Bologna and University of All patients reassessment reassessment Bologna, Bologna/IT 11 Hospital Universitario Gregorio Marañón, Madrid/ES Cancer (N=142) (n=121) (n=21) Centre of Southeastern Ontario at Kingston General Hospital, Kingston/ON/CA, Arnaud de ORR at pre-Sx/pre-CRT, n (%; 95% CI)b.d. - Villeneuve University Hospital of Montpellier, Montpellier/FR, 14 Hôpital Saint Joseph, 76 (62.8; 53.6-71.4) 4 (19.0; 5.4-41.9) Marseille/FR, ⁵European Institute of Oncology, IRCCS, Milan/IT AstraZeneca, pCR, n (%; 95% CI) 33 (23.2; 16.6-31.1) 33 (27.3; 19.6-36.1) - Mississauga/ON/CA, AstraZeneca, Gaithersburg/MD/USA, AstraZeneca, - Wilmington/DE/USA McGill University, Montreal/QC/CA 3:27 PM - 3:37 PM 12-month EFS rate, % (95% CI)d 88.5 (81.5-92.9) 90.1 (82.8-94.4) 10m View abstract @ View biography 12-month PFS rate, % (95% - - 75.1 (45.2-90.2) Introduction: In AEGEAN (NCT03800134), perioperative durvalumab + neoadjuvant CT significantly improved pCR and EFS in patients with resectable NSCLC versus neoadjuvant Adjuvant/consolidation durvalumab period CT alone. In PACIFIC (NCT02125461), consolidation durvalumab significantly improved PFS Received adjuvant Received consolidation and OS in patients with unresectable stage III NSCLC after CRT. The phase 2 MDT-BRIDGE Overall study period durvalumab after durvalumab after study is investigating perioperative durvalumab plus neoadjuvant CT in patients with (N=142) surgery (n=94) CRT (n=23) resectable/borderline resectable NSCLC and evaluating if CRT followed by consolidation durvalumab is effective and tolerable in patients who become unresectable during Any-grade, all-cause AEs, n (%) 140 (98.6) 83 (88.3) 19 (82.6) neoadjuvant treatment. Here, we report efficacy and safety data from the primary analysis. Maximum grade 3 or 4 67 (47.2) 7(7.4) 4 (17.4) Methods: MDT-BRIDGE (NCT05925530) is a global non-randomized study in treatment- naive patients with EGFR /ALK wild-type, stage IIB-IIIB NSCLC. Following initial Serious AEs 41 (28.9) 10 (10.6) 4 (17.4) multidisciplinary team (MDT) resectability assessment, patients received 2 cycles of neoadjuvant durvalumab + CT Q3W IV followed by MDT reassessment. Patients deemed Outcome of death 3 (2.1) 0 1 (4.3) resectable at reassessment received 1-2 more cycles of neoadjuvant durvalumab + CT, Leading to discontinuation of durvalumab 19 (13.4) 8 (8.5) 3 (13.0) followed by surgery; patients deemed unresectable received standard-of-care CRT for ~6 weeks. After surgery/CRT, all patients received durvalumab Q4W IV for up to 1 year. Primary Any-grade immune-mediated AEs, n (%) 27 (19.0) 14 (14.9) 3 (13.0) endpoint: resection rate in all patients. Secondary endpoints included resection rate by baseline resectability, EFS, PFS, ORR, OS, pCR, resection outcomes (R0/R1/R2), and safety. Maximum grade 3 or 4 4 (2.8) 1 (1.1) 0 Results: As of January 12, 2026 (data cutoff), 142 patients had received neoadjuvant Any-grade pneumonitis, n (96) 13 (9.2) 6 (6.4) 2 (8.7) treatment of whom 64.8% and 35.2% were deemed resectable and borderline resectable at baseline, respectively (Table). Overall, 131 patients (92.3%) had either surgery (n=106) or Maximum grade 3 or 4 1 (0.7) 0 0 CRT (n=25) after neoadjuvant durvalumab + CT, and 117 patients (82.4%) subsequently received adjuvant (n=94) or consolidation (n=23) durvalumab, respectively. The resection "Defined as the proportion of patients who started resection. "Cis calculated by Clopper-Pearson exact method. Percentages based on the number of patients who started resection. "Efficacy outcomes reported for prespecified analysis populations except pCR (by local pathology review), which was not prespecified for rate in all patients was 74.6% with an R0 resection rate of 96.2%. In patients deemed analysis in all patients. "Unconfirmed complete or partial response as assessed by the investigator per RECIST version 1.1, with baseline defined by the screening resectable at MDT reassessment (n=121), the pCR rate was 27.3% and the 12-month EFS scan. Calculated by Kaplan-Meier method, with Cis calculated by Brookmeyer-Crowley method. 'Based on 14.1% maturity and median EFS follow-up of 10.9 rate was 90.1%. In patients deemed unresectable at MDT reassessment (n=21), the 12- months in all (censored) patients, with EFS defined as the time from the first dose of any study treatment to the earliest of: (A) PD that precluded surgery (or, month PFS rate was 75.1%. During adjuvant/consolidation durvalumab, maximum all-cause for patients who did not have surgery for a reason other than progression, PD, per RECIST version 1.1, after MDT reassessment); (B) PD discovered and reported by the investigator upon attempting surgery that prevented completion of surgery (or, for patients who did not complete surgery for a reason other than grade 3/4 AEs occurred in 7.4% (resected cohort) and 17.4% (CRT-treated cohort), progression, PD, per RECIST version 1.1, after surgery); (C) local/distant recurrence as assessed by the investigator per RECIST version 1.1; or (D) death from any respectively, and 8.5% and 13.0% had AEs leading to discontinuation of durvalumab. cause. "Based on 23.8% maturity and median PFS follow-up of 7.3 months in all (censored) patients deemed unresectable at reassessment, with PFS defined as Conclusions: In MDT-BRIDGE, the overall resection rate was 74.6% in a population that the time from the first dose of any study treatment until PD, assessed by the investigator per RECIST version 1.1, or death (by any cause in the absence of included more than one-third of patients with borderline resectable disease. Close MDT progression) regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to PD. Included one patient each with follow-up allowed most patients to receive curative-intent treatment (92.3% had cardiac failure (during consolidation durvalumab), interstitial lung disease, and death (not otherwise specified). No patients had grade 5 immune-mediated AEs. A grouped term that includes immune-mediated lung disease, interstitial lung disease, and pneumonitis. One patient had grade 5 pneumonitis (grouped term), surgery/CRT) and post-definitive therapy (82.4% had adjuvant/consolidation durvalumab). post-surgery. AE, adverse event; CI, confidence interval; CRT, chemoradiotherapy; EFS, event-free survival; MDT, multidisciplinary team; ORR, objective Finally, preliminary efficacy outcomes were encouraging, and the adjuvant and response rate; pCR, pathological complete response; PD, progressive disease; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid consolidation safety profiles were consistent with prior studies. Tumors; Sx, surgery.

15sac-TMT4.2K impressions2.1K primary · 2.1K preview26 engagements2 posts · 2 voices▾

MMinhua Chu@chuminhua432

🇨🇳Kelun-Biotech reported new data for TROP2 ADC sac-TMT at #WCLC2026 for pretreated NSCLC with actionable genomic alterations beyond classic EGFR mutations.

Ph2 multicohort study (NCT05631262), n=90, incl. EGFR G719X/S768I/L861Q, EGFR ex20ins, ALK fusion, KRAS mutation, ROS1 fusion/other. Median 2 prior lines; 68.9% prior platinum chemo.

At 21.2mo median follow-up:
- ORR 34.4% (31/90)
- Median D

2.1K impressions14 likes6 reposts2026-08-20

[Slide 1] Proprietary ROS1/RET fusion, MET ex14 Total EGFR non-classic EGFR ex20ins ALK fusion KRAS mutation (N=90) skipping, or BRAF V600E (n=23) (n=20) (n=20) (n=16) (n=11) ORR, % 34.4 39.1 35.0 40.0 25.0 27.3 (95% CI) (24.7, 45.2) (19.7, 61.5) (15.4, 59.2) (19.1, 63.9) (7.3, 52.4) (6.0, 61.0) DCR, % 85.6 91.3 75.0 95.0 75.0 90.9 (95% CI) (76.6, 92.1) (72.0, 98.9) (50.9, 91.3) (75.1, 99.9) (47.6, 92.7) (58.7, 99.8) Median DOR, mo 12.7 12.7 12.8 7.6 NR 14.7 (95% CI) (7.6, 14.9) (7.4, NE) (3.9, NE) (0.6, NE) (3.9, NE) (2.4, NE) Median PFS, mo 9.4 10.9 9.0 9.4 9.6 7.1 (95% CI) (5.7, 11.5) (5.6, 19.3) (1.9, 13.7) (3.7, NE) (1.7, 16.6) (1.7, 19.1) 12-mo PFS rate, % 38.9 45.5 37.9 43.0 28.1 33.8 (95% CI) (28.0, 49.5) (24.4, 64.3) (17.3, 58.5) (19.8, 64.4) (6.8, 55.0) (8.0, 62.7) Median os, mo NR NR 21.3 23.3 12.3 NR (95% CI) (19.1, NE) (19.7, NE) (15.7, NE) (8.0, NE) (7.6, NE) (8.6, NE) 18-mo OS rate, % 64.7 78.3 74.3 60.0 47.1 54.5 (95% CI) (53.7, 73.7) (55.4, 90.3) (48.7, 88.4) (35.7, 77.6) (21.6, 69.1) (22.9, 78.0) Note: EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; KRAS, kirsten rat sarcoma viral oncogene homolog; ROS1, ROS proto-oncogene 1 receptor tyrosine kinase; RET, proto-oncogene tyrosine-protein kinase receptor Ret; MET, mesenchymal-epithelial transition factor; BRAF, v-raf murine sarcoma viral oncogene homolog B; ORR, objective response rate; DCR, disease control rate; DOR, duration of response; PFS, progression-free survival; OS, overall survival. [Slide 2] Abstract details Introduction: Sacituzumab tirumotecan (sac-TMT) is a TROP2 ADC developed with a unique bifunctional linker to conjugate a belotecan- derivative topoisomerase I inhibitor. Sac-TMT has shown encouraging antitumor activity in NSCLC patients (pts) with classic EGFR mutations (Fang et al., BMJ 2025; Fang et al., NEJM 2025). These findings led to the marketing approval of sac-TMT for EGFR-mutant NSCLC in China. Here we present the preliminary efficacy and safety of sac-TMT in previously treated pts with advanced NSCLC harboring other actionable genomic alterations (AGAs) from the phase 2, open-label, multicohort study in China (NCT05631262). Methods: Pts with advanced NSCLC harboring various genomic alterations who had progressed on or after standard therapy were enrolled in this study. Pts received sac-TMT 5 mg/kg Q2W until disease progression or unacceptable toxicity. Tumor response was assessed per RECIST v1.1 by investigator every 8 weeks for the first 48 weeks, and every 12 weeks thereafter. Sac-TMT in Pts With Previously Results: As of 11 Dec 2025, 90 pts (median age 59 years; 43.3% male) were enrolled, including 23 pts with EGFR G719X in exon 18, S768I in Treated Advanced NSCLC With exon 20, or L861Q in exon 21, 20 pts with EGFR ex20ins, 20 pts with ALK fusion, 16 pts with KRAS mutation and 11 pts with ROS1 fusion or other gene abnormalities. The median number of prior treatment regimens for advanced disease was 2 and 68.9% of pts had received Actionable Genomic platinum-based chemotherapy. After a median follow-up of 21.2 months (mo), sac-TMT monotherapy showed promising and durable anti- Alterations Other Than Classic tumor activity across AGA subgroups with an ORR of 34.4% (31/90) and a median DOR of 12.7 mo (Table). Grade ≥ 3 treatment-related EGFR Mutations adverse events (TRAEs) occurred in 56.7% of pts and treatment-related serious adverse events (TRSAEs) in 18.9% of pts. The most frequent grade ≥3 TRAEs (≥5%) were neutrophil count decreased (42.2%), WBC count decreased (24.4%), anemia (17.8%) and stomatitis (7.8%). No TRAE led to treatment discontinuation or death. Conclusions: Sac-TMT monotherapy demonstrated promising clinical activity with a manageable safety profile in previously treated advanced NSCLC pts with advanced NSCLC harboring AGAs other than classic EGFR mutations. These findings warrant further investigation of sac-TMT Proprietary ROSURET fusion, METex14 Total EGFR non-classic EGFR ex20ins ALK fusion KRAS mutation (N-90) skipping, BRAF V600E (n=23) (n=20) (m=20) (a=16) (n-11) ORR.% % 34.4 39.1 35.0 40.0 25.0 27.3 (95%CI) (24.7,45.2) (19.7.61.5) (15.4,59.2) (19.1,63.9) (0.52.) (6.0,61.0) DCR,% 85.6 91.3 75.0 95.0 75.0 90.9 (95%CI) (76.6,92.1) (72.0,98.9) (50.9,91.3) (75.1,99.9) (47.6,92.7) (58.7,99.8) Median DOR. mo 12.7 12.7 12.8 7.6 NR 14.7 (95%CI) (7.6,14.9) (7.4,NE) (3.9,NE) (0.6,NE) (3.9,NE) (2.4,NE)

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Oral Session
🔥Sacituzumab Tirumotecan (Sac-TMT) in Pts With Previously Treated Advanced NSCLC With Actionable Genomic Alterations Other Than Classic EGFR Mutations
🎙️Dr. Wenfeng Fang
🔢OA10.03
🎯ORR 34.4%, mDOR 12.7m (EGFR Non-Classic, Ex20ins, ALK, KRAS, ROS1/RET)
🎯No TRAE Led to Death
☑️NCT05631262
🔗 https://t.co/luSCKZgoHw
@OncoAlert @Larvol @IASLC @Exon20Group @ALKPositiveinc @KRA

2.1K impressions29 likes9 reposts2026-08-22

[Slide 1] OA10.03. Sac-TMT in Pts With Previously Treated Advanced NSCLC With Actionable Introduction: Sacituzumab tirumotecan (sac-TMT) is a TROP2 ADC developed with a Genomic Alterations Other Than Classic EGFR Mutations unique bifunctional linker to conjugate a belotecan-derivative topoisomerase I inhibitor. W. Fang¹, X. Zhang², R. Yang³, X. Li⁴, Q. Wang⁵, Y. Zhang⁶, X. Meng⁷, L. He⁸, G. Sac-TMT has shown encouraging antitumor activity in NSCLC patients (pts) with classic Jiang⁹, W. Zheng¹⁰, Z. Zhang¹¹, J. Cui¹², Y. Xie¹³, H. Wang¹⁴, B. Chen¹⁴, M. EGFR mutations (Fang et al., BMJ 2025; Fang et al., NEJM 2025). These findings led to the Zhuo¹⁵, W. Yao¹⁶, Y. Yao¹⁷, Y. Yu¹⁸, P. Chen¹⁹, X. Du²⁰, J. Yang²¹, Y. Diao²¹, J. marketing approval of sac-TMT for EGFR-mutant NSCLC in China. Here we present the Ge²², L. Zhang preliminary efficacy and safety of sac-TMT in previously treated pts with advanced NSCLC Sun Yat-sen University Cancer Center, Guangzhou/CN Jilin Provincial Cancer Hospital, harboring other actionable genomic alterations (AGAs) from the phase 2, open-label, multicohort study in China (NCT05631262). Changchun/CN The Third Affiliated Hospital of Kunming Medical University, Kunming/CN Methods: Pts with advanced NSCLC harboring various genomic alterations who had 4The First Affiliated Hospital of Zhengzhou University, Zhengzhou/CN ⁵The Affiliated progressed on or after standard therapy were enrolled in this study. Pts received sac-TMT Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Academy of 5 mg/kg Q2W until disease progression or unacceptable toxicity. Tumor response was Innovations in Medical Science, Zhengzhou/CN ⁶Hunan Cancer Hospital/The Affiliated assessed per RECIST v1.1 by investigator every 8 weeks for the first 48 weeks, and every Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha/CN 12 weeks thereafter. Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan/CN Results: As of 11 Dec 2025, 90 pts (median age 59 years; 43.3% male) were enrolled, ⁸Chengdu Fifth People's Hospital, Chengdu/CN 9Dongguan People's Hospital, including 23 pts with EGFR G719X in exon 18, S7681 in exon 20, or L861Q in exon 21, 20 Dongguan/CN, Shengjing Hospital, China Medical University, Shenyang/CN The First pts with EGFR ex20ins, 20 pts with ALK fusion, 16 pts with KRAS mutation and 11 pts with Affiliated Hospital of Henan University of Science and Technology, Luoyang/CN, The First ROS1 fusion or other gene abnormalities. The median number of prior treatment regimens Hospital of Jilin University, Changchun/CN, 13 The People's Hospital of Guangxi Zhuang for advanced disease was 2 and 68.9% of pts had received platinum-based chemotherapy. Autonomous Region, Nanning/CN, 14 Hunan Cancer Hospital, Changsha/CN Beijing After a median follow-up of 21.2 months (mo), sac-TMT monotherapy showed promising and durable anti-tumor activity across AGA subgroups with an ORR of 34.4% (31/90) and a Cancer Hospital, Beijing/CN, University of Electronic Science and Technology of China, Sichuan Cancer Hospital and Institute & Cancer, The Second People's Hospital of Sichuan median DOR of 12.7 mo (Table). Grade ≥ 3 treatment-related adverse events (TRAEs) Province, Chengdu/CN, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an/CN occurred in 56.7% of pts and treatment-related serious adverse events (TRSAEs) in 18.9% 18 Harbin Medical University Cancer Hospital, Harbin/CN, Tianjin Medical Unversity of pts. The most frequent grade ≥3 TRAEs (≥5%) were neutrophil count decreased Cancer Institute & Hospital, Tianjin/CN Mianyang Central Hospital, School of Medicine, (42.2%), WBC count decreased (24.4%), anemia (17.8%) and stomatitis (7.8%). No TRAE led to treatment discontinuation or death. University of Electronic Science and Technology of China, Mianyang/CN 21 Sichuan Kelun- Conclusions: Sac-TMT monotherapy demonstrated promising clinical activity with a Biotech Biopharmaceutical Co., Ltd., Chengdu/CN 22 Sichuan Kelun-Biotech manageable safety profile in previously treated advanced NSCLC pts with advanced NSCLC Biopharmaceutical Co., Ltd., National Engineering Research Center of Targeted Biologics, harboring AGAs other than classic EGFR mutations. These findings warrant further Chengdu/CN L 12:22 PM - 12:32 PM 10m View abstract Jo View biography investigation of sac-TMT as a potential therapv for this population. Proprietary ROSI/RET fusion, MET ex14 Total EGFR non-classic EGFR ex20ins ALK fusion KRAS mutation (N=90) skipping, or BRAF V600E (n=23) (n=20) (n=20) (n=16) (n=11) ORR, % 34.4 39.1 35.0 40.0 25.0 27.3 (95% CI) (24.7, 45.2) (19.7,61.5) (15.4,59.2) (19.1, 63.9) (7.3, 52.4) (6.0,61.0) DCR, % 85.6 91.3 75.0 95.0 75.0 90.9 (95% CI) (76.6, 92.1) (72.0, 98.9) (50.9, 91.3) (75.1, 99.9) (47.6, 92.7) (58.7, 99.8) Median DOR, mo 12.7 12.7 12.8 7.6 NR 14.7 (95% CI) (7.6, 14.9) (7.4, NE) (3.9, NE) (0.6, NE) (3.9, NE) (2.4, NE) Median PFS, mo 9.4 10.9 9.0 9.4 9.6 7.1 (95% CI) (5.7, 11.5) (5.6, 19.3) (1.9, 13.7) (3.7, NE) (1.7, 16.6) (1.7, 19.1) 12-mo PFS rate, % 38.9 45.5 37.9 43.0 28.1 33.8 (95% CI) (28.0, 49.5) (24.4, 64.3) (17.3, 58.5) (19.8, 64.4) (6.8, 55.0) (8.0, 62.7) Median os, mo NR NR 21.3 23.3 12.3 NR (95% CI) (19.1, NE) (19.7, NE) (15.7, NE) (8.0, NE) (7.6, NE) (8.6, NE) 18-mo OS rate, % 64.7 78.3 74.3 60.0 47.1 54.5 (95% CI) (53.7,73.7) (55.4, 90.3) (48.7, 88.4) (35.7,77.6) (21.6, 69.1) (22.9, 78.0) Note: EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; KRAS, kirsten rat sarcoma viral oncogene homolog; ROS1, ROS proto-oncogene 1 receptor tyrosine kinase; RET, proto-oncogene tyrosine-protein kinase receptor Ret; MET, mesenchymal-epithelial transition factor; BRAF, v-raf murine sarcoma viral oncogene homolog B; ORR, objective response rate; DCR, disease control rate; DOR, duration of response; PFS, progression-free survival; OS, overall survival.

16HALT3K impressionsall primary28 engagements1 posts · 1 voices▾

DDrew Moghanaki@DrewMoghanaki

A research question worth investigating to assess this problem is whether SBRT delays time to SCLC transformation in mEGFR tumors at risk. The HALT & NORTHSTAR study results can shed light on that. @fifimcdrmh #WCLC26 https://t.co/KOxkg6kopY

3K impressions16 likes4 reposts2026-08-25

17NORTHSTAR3K impressionsall primary28 engagements1 posts · 1 voices▾

DDrew Moghanaki@DrewMoghanaki

3K impressions16 likes4 reposts2026-08-25

18STARLORDpreview only2.8K impressionsno primary data posted yet1 posts · 1 voices▾

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Oral Session
🔥STARLORD: Stereotactic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer Unfit for Concurrent Chemoradiation
🎙️ @FraCuccia
🔢OA09.04
🎯1y Local Control 92.3%
🎯1y OS 90.9%
🎯No Late Grade≥3 Toxicities
🎯Worse Outcomes in Stage IIIC and Age ≥75
🔗 https://t.co/ziJuI9A5M1
@OncoAlert @Larvol @IASLC

2.8K impressions12 likes4 reposts2026-08-22

[Slide 1] OA09.04. Stereotactic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer Unfit for Concurrent Chemoradiation: The STARLORD Study F. Cuccia¹, M. Campione¹, G. Mortellaro¹, V. Figlia¹, A. Spera¹, C. Napoli¹, S. D'Alessandro¹, L. Blasi¹, F. Verderame², F. Azzarello¹, G. Failla¹, G. Carruba¹, G. Ferrera¹ 1 ARNAS Civico Hospital, Palermo/IT 2 AOOR Villa Sofia - Cervello Ospedali Riuniti, Palermo/IT 4 12:32 PM - 12:42 PM 10m View abstract Jo View biography Introduction: For patients with unresectable stage III non-small cell lung cancer (NSCLC) ineligible for concurrent chemo-radiation, stereotactic body radiotherapy(SBRT) may provide a favorable efficacy-toxicity balance Methods: STARLORD is a prospective mono-institutional phase II study evaluating safety, tolerability, and early outcomes of SBRT after chemotherapy for locally-advanced NSCLC. The primary endpoint was acute G≥3 cardiopulmonary toxicity assessed using CTCAE v5.0. Secondary endpoints included local control (LC), distant progression-free survival (DPFS), overall survival (OS), late toxicity. Time-to-event analyses were complemented by penalized Cox (ridge) models. Results: Twenty-six consecutive patients with stage IIIB-IIIC NSCLC were analyzedwith median age 75.5 years, with 84.6% of patients presenting stage IIIB disease and 15.4% stage IIIC. Following induction chemotherapy, SBRT was delivered to both the primary tumor and mediastinal disease in 5 fractions, for median total doses respectively of 40 Gy (range 40-50 Gy) and 35 Gy (range 35-40 Gy). Consolidation immunotherapy was administered in 76.9% of patients. After a median follow-up of 17.3 months, acute G3 dysphagia was observed in 7.7%, no late grade ≥3 toxicities were observed. The 1-year local control (LC) rate was 92.3%, with two mediastinal progressions occurring 11 and 12 months after SBRT. Median distant progression-free survival (DPFS) was 15.6 months with a 1-year DPFS rate of 56.7%. Four deaths were recorded during follow-up, resulting in a 1-year overall survival (os) rate of 90.9%, with worse outcomes for patients with stage IIIC disease (log-rank p = 0.00027) and aged ≥75 years (log-rank p = 0.032). Conclusions: Our study supports the feasibility of SBRT after chemotherapy for patients with unresectable stage III NSCLC ineligible for concurrent chemo-radiation. Dose-response signals and the prognostic impact of late toxicity warrant validation in larger cohorts with longer follow-up.

19HARMONi-62.6K impressionsall primary34 engagements1 posts · 1 voices▾

MMinhua Chu@chuminhua432

2.6K impressions19 likes5 reposts2026-08-21

20BNT327 (pumitamig)2.1K impressions528 primary · 1.6K preview2 engagements4 posts · 4 voices▾

AAnton@seahorse_anton

BioNTech SE $BNTX – $116.57 | Aug 23, 2026
Next-generation biopharmaceutical pioneer transitioning from COVID-19 vaccine leader (Comirnaty®) to an oncology biopharma enterprise. Its late-stage pipeline features pumitamig (BNT327, PD-L1xVEGF-A bispecific co-developed with Bristol Myers Squibb), gotistobart (anti-CTLA-4), ADCs (DualityBio collaborations), and individualized mRNA immunotherapies. We

352 impressions0 likes0 reposts2026-08-23

[Slide 2] BNTX I Weekly Ichimoku Cloud Architecture I Bias: BULLISH 120 Kumo (Bullish) Kumo (Bearish) $116.57 Weekly Close Tenkan (9) 115 Kijun (26) 110 105 100 95 90 85 2025 -03-01 2025-05-01 2025-07-01 2025 09-01 2025-11-01 2026-01-01 2026-03-01 2026-05-01 2026-07-01 2026-09-01 BNTX I Daily Keltner Bounds & Elastic VWAP Channels (Last Market Close: 2026-08-21) CURRENT: $116.57 Daily Close 115 KC Base EMA (20) KC Upper Band KC Lower Band 110 Static Prior-Week VWAP Developing Current-Week VWAP Elastic Extension Limit (85% Rolling Max) 105 100 95 90 85 80 2026-03-01 2026-04-01 2026-05-01 2026-06-01 2026-07-01 2026-08-01 Seahor: Invest www.seahorse-invest. com Adaptive Dual-Gate Output Frame

NNick@Lawbitrage

@SamFazeli8 Oh, and now also these Pumitamig data in peritoneal mesothelioma from the WCLC 2026 abstracts: https://t.co/mfgMf5RoTr

130 impressions0 likes0 reposts2026-08-26

MMolecule Trader@molecule_trader

We should get another useful look at BioNTech’s lung cancer work soon.

At the World Conference on Lung Cancer in Seoul, September 12 to 15, BioNTech plans to present new data across pumitamig, gotistobart and its mRNA programmes. That includes preliminary BNT116 data in resectable NSCLC.

One distinction matters: those BNT116 results are not from the EGFR plus osimertinib cohort I mentioned above

46 impressions1 likes0 reposts2026-08-25

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Mini Oral Session
🔥First-Line Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy in Unresectable Malignant Mesothelioma: Long-Term PFS and OS
🎙️Dr. Liang Zhang
🔢MO04.09
🎯cORR 51.6%, DCR 93.5%
🎯mPFS 16.6m, mOS 25.8m
🎯No New Safety Signals
☑️NCT05918107
🔗 https://t.co/xJ8uXBQA72
@OncoAlert @Larvol @IASLC

1.6K impressions10 likes5 reposts2026-08-25

[Slide 1] MO04.09. First-Line Pumitamig (PD-L1 x VEGF-A bsAb) Plus Chemotherapy in Unresectable Malignant Mesothelioma: Long-Term PFS and OS H. Liu¹, L. Lu², W. Zhuang³, D. Zhu⁴, Y. Zhao⁵, N. Li⁶, Y. Guo⁷, Z. Hui⁸, Y. Li⁹, Z. MPM MPeM Wang¹⁰, P. Zhang¹¹, Y. Wang¹², J. Zhang¹³, L. Chen¹³, J. Liu¹³, M. Chen¹⁴, U. Overall Gunaydin I. Celik¹⁶, L. Zhang¹ Overall Epithelioid Overall Epithelioid 1 Jilin Cancer Hospital, Changchun/CN ²Zhejiang Provincial People's Hospital, Hangzhou/CN N = 31 ,³Fujian Cancer Hospital, Fuzhou/CN, 4Shandong Cancer Hospital, Jinan/CN, ⁵Henan Cancer n = 23 n = 13 n=8 n=6 = Hospital, Zhengzhou/CN ⁶The First Hospital of Hebei Medical University, Shijiazhuang/CN 7The First Affiliated Hospital, Sun Yat-sen University, Guangzhou/CN ⁸Chinese Academy of Medical Sciences, Beijing/CN ⁹Chongqing University Cancer Hospital, Chongqing/CN mPFS, months 16.6 15.8 15.8 25.1 19.5 ¹⁰peking Cancer Hospital, Beijing/CN ¹Shanghai Pulmonary Hospital, Shanghai/CN Affiliated Cancer Hospital of Harbin Medical University, Harbin/CN ¹³BioNTech (Zhuhai) (95% CI) (9.9-19.3) (8.5-17.3) (6.9-19.3) (16.2-NE) (7.7-NE) Pharmaceuticals R&D Co., Ltd, Guangdong/CN, ¹⁴BioNTech, Shanghai/CN, ¹⁵BioNTech US Inc., Cambridge/MA/USA, ¹⁶BioNTech SE, Mainz/DE 5:43 PM - 5:48 PM 5m View abstract Jo View biography 24-month PFS rate, % 25.2 18.3 23.1 50.0 40.0 Introduction: Malignant mesothelioma is a rare neoplasm with high unmet medical need. Pumitamig (BNT327/BMS986545), a bispecific antibody targeting PD-L1 and VEGF-A, has shown encouraging confirmed overall response rate (cORR) and progression-free survival (95% CI) (11.2-42.1) (5.7-36.5) (5.6-47.5) (11.1-80.4) (5.2-75.3) (PFS) signals in a phase 2 trial in patients with treatment-naive malignant mesothelioma (Cheng Y, et al. Presented at ASCO 2025, Abstract 8511). We now present long-term PFS and overall survival (OS) results from this trial. mos, months 25.8 23.5 23.5 27.1 27.1 Methods: Patients aged ≥18 years with unresectable, treatment-naive malignant mesothelioma (pleural [MPM] or peritoneal [MPeM]) were enrolled in this ongoing, (95% CI) (20.4-NE) (20.4-NE) (15.8-NE) (7.4-NE) (11.8-NE) multicenter, single-arm phase 2 trial. Patients received pumitamig 30 mg/kg every three weeks plus 4-6 cycles pemetrexed/platinum, followed by pumitamig maintenance. We report the key secondary endpoints of PFS and OS after a median follow-up of 23.5 months 24-month os rate, % 50.7 46.2 46.2 62.5 66.7 (data cutoff: October 18, 2025), along with updated cORR and safety. Results: Thirty-one patients enrolled, of which 23 had MPM and 8 had MPeM. Median PFS (mPFS) was 16.6 months, with a 24-month PFS rate of 25.2%. Median OS (mOS) was 25.8 (95% CI) (32.0-66.7) (25.1-65.0) (19.2-69.6) (22.9-86.1) (19.5-90.4) months, with a 24-month OS rate of 50.7%. In patients with MPM, mPFS was 15.8 months and mos was 23.5 months; in patients with MPeM, mPFS was 25.1 months and mOS was 27.1 months. Outcomes in epithelioid histology are shown in the Table. Tumor response cORR, % 51.6 43.5 30.8 75.0 83.3 data was as previously reported. cORR was 51.6% (95% confidence interval [CI] 33.1-69.8), with a median duration of response (mDOR) of 11.1 months (95% CI 6.4-17.8); disease (95% CI) (33.1-69.8) (23.2-65.5) (9.1-61.4) (34.9-96.8) (35.9-99.6) control rate (DCR) was 93.5% (95% CI 78.6-99.2). Median time on treatment was 62.2 weeks (range 6.0-140.1), with 1 patient remaining on treatment. All patients experienced treatment-related adverse events (TRAEs; related to mDOR, months 11.1 9.7 11.1 16.3 11.4 pumitamig and/or chemotherapy), which were grade ≥3 in 29/31 (93.5%) patients. Immune-related adverse events occurred in 11 (35.5%) patients and were of grade ≥3 in 2 (6.5%) patients (1 with interstitial lung disease, 1 with dermatitis). Hemorrhage/bleeding (95% CI) (6.4-17.8) (6.3-17.8) (6.3-NE) (4.8-NE) (4.8-NE) events occurred in 4 (12.9%) patients; all were grade 1-2 and none led to treatment modifications. Five patients (16.1%) discontinued treatment due to TRAEs, and there were no treatment-related deaths. DCR, % 93.5 91.3 92.3 100.0 100.0 Conclusions: First-line pumitamig plus chemotherapy was efficacious in patients with malignant mesothelioma (MPM and MPeM), with particularly encouraging long-term (95% CI) (78.6-99.2) (72.0-98.9) (60.4-99.8) (63.1-100.0) (54.1-100.0) survival outcomes (PFS and OS) regardless of tumor type and histology and without any new safety signals, suggesting that further development of pumitamig in malignant mesothelioma is warranted. NE, not estimable.

21GFH375 (KRAS G12D)2K impressions296 primary · 1.7K preview5 engagements3 posts · 3 voices▾

ggilberto lopes@GlopesMd

3. OA12.01 — GFH375 (VS-7375) in KRAS G12D NSCLC. First-in-class oral drugging of a non-cysteine KRAS allele. G12D is ~4% of lung, but the chemistry precedent runs well past G12D. @VerastemOncolog @IASLC #WCLC26 #LCSM https://t.co/ctRSqg5V7G

296 impressions2 likes1 reposts2026-08-27

[Slide 1] GFH375 targets both active and inactive KRAS G12D IC₅₀ to active, GppNHp-bound KRAS G12D: 2 nM (KRAS-RAF1 binding assay) Laser Laser FRET No FRET D D A A GFH375 Tag Tag Tag Tag 2 1 2 GPPNP 1 KRAS KRAS GPPNP RAF1 RAF1 IC₅₀ to inactive, GDP-bound KRAS G12D: 6 nM (nucleotide exchange assay) Laser Laser Laser D FRET FRET No FRET GFH375 GDP A Tag A A SOS1 Tag Tag GDP GDP GTP SOS1 GTP KRAS KRAS GTP KRAS GTP

From session previews

HHidehito HORINOUCHI@HHorinouchi

🆙#WCLC26 #LCSM Oral Session
🔥Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant NSCLC Patients
🎙️Dr. Z. Li
🔢OA12.01
🎯At RP2D 600mg QD, Confirmed ORR 49.1%, DCR 90.6%
🎯Median PFS 8.1m, OS 15.4m
🎯Grade≥3 TRAEs in 33.3%
☑️NCT06500676
🔗 https://t.co/tHSHNAWldb
@OncoAlert @Larvol @IASLC @KRASKickers

1.1K impressions6 likes0 reposts2026-08-23

[Slide 1] OA12.01. Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant Non-Small Introduction: Kirsten rat sarcoma (KRAS) mutation occurs in approximately 4% of non- Cell Lung Cancer (NSCLC) Patients small cell lung cancer (NSCLC) cases and is associated with worse prognosis. GFH375, a S. Lu¹, Z. Li¹, X. Ai¹, P. Chen², W. Yao³, H. Zong⁴, L. Wu⁵, T. Zhang⁶, J. He⁷, Q. potent and highly selective orally bioavailable inhibitor of KRASG¹²D (ON/OFF) under clinical development, has shown encouraging anti-tumor efficacy in patients with Yu7, Z. Niu⁸, Y. Sun⁸, J. Fang⁹, J. Xue¹⁰, A. Li¹¹, K. Tang¹², L. Zhu¹³, Z. Song¹⁴, advanced solid tumors such as NSCLC, pancreatic ductal adenocarcinoma and other Y. Yuan 15 M. Sun Zhao¹⁷, Y. Du¹⁸, Y. Wang¹⁹, H. Shen¹⁹, H. Zhu¹⁹, C. tumors. Herein, we report the efficacy, safety and biomarker data from NSCLC patients Zheng Y. Shan¹⁹, Z. Cui¹⁹ treated at recommended phase II dose of GFH375 ( 600 mg once daily) in the phase I/II study (NCT06500676). Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University Methods: Eligible patients who had advanced KRASG¹²D mutant NSCLC and failed to prior School of Medicine, Shanghai/CN 2Department of Thoracic Oncology, Tianjin Medical therapies were enrolled in the phase I backfilling and phase II parts receiving GFH375 600 University Cancer Institute & Hospital, Tianjn/CN, ³Department of Thoracic Medical mg once daily (QD). Primary endpoint in phase II was objective response rate (ORR) Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Secondary endpoints included duration of response (DoR), disease control rate (DCR), progression Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and free survival (PFS), safety and overall survival (OS). Technology of China, Chengdu/CN, ⁴Department of Medical Oncology, The First Affiliated Results: As of 31-Oct-2025, a total of 57 NSCLC patients (66.7% male, median age 62) Hospital of Zhengzhou University, Zhengzhou/CN ⁵The Department of Thoracic Medical were enrolled. All had metastatic disease at baseline. Fifty-four (94.7%) were Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of adenocarcinoma. Twenty-seven (47.4%) were never-smokers. Fifty (87.7%) had Eastern Cooperative Oncology Group performance status (ECOG PS) 1 at baseline. Thirty-nine Medicine, Central South University, Changsha/CN, Third Ward, Department of Oncology, patients had baseline PD-L1 TPS reported: 19 (48.7%), 13 (33.3%) and 7 (17.9%) patients Beijing Chest Hospital, Capital Medical University, Beijing/CN Medical Oncology of with TPS <1%, 1%-49% and 50%, respectively. Twenty-four (42.1%) patients received at Respiratory, Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute, least 2 prior lines of systemic therapies. All patients received prior anti-PD1/PD-L1 therapy Guangxi Cancer Hospital & Medical University Oncology School & Cancer Center, and platinum-based chemotherapy. As of 31-Mar-2026, the minimum follow-up time was 5.0 months. Among the 53 patients who had at least one post-treatment tumor Nanning/CN ⁸Department of Gastroenterology/Department of Phase I clinical trial center, assessment, ORR was 54.7% (95%CI: [42.6%, 66.5%]); confirmed ORR was 49.1% (95%CI: Shandong Cancer Hospital, Shandong First Medical University, Jinan/CN, 9Division 2, [37.1%, 61.1%]), with median DoR of 11.0 months (95%CI: [5.6, NA]); DCR was 90.6% Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Beijing/CN (95%CI: [81.2%, 96.2%]). Median PFS and OS was 8.1 months and 15.4 months, Department of Thoracic Oncology, West China School of Medicine, West China Hospital respectively. Treatment-related adverse events (TRAEs) with grade ≥3 and serious AEs occurred in 33.3% and 17.5% of patients. One patients (1.8%) discontinued treatment, 12 of Sichuan University, Chengdu/CN 11 Division 1, Department of Pulmonary Medicine, (21.1%) had dose reduction and 18 (31.6%) had dose interruption due to TRAEs. The most Guangdong Provincial People's Hospital, Guangzhou/CN, 12 Department of Respiratory and common TRAEs (reported in ≥20% patients) were diarrhea, vomiting, nausea, aspartate Critical Care Medicine, The first Affiliated Hospital, Sun Yat-sen University, Guangzhou/CN aminotransferase increased, hypertriglyceridaemia, alanine aminotransferase increased, 13 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, anemia, neutrophil count decreased, hyponatraemia, proteinuria, decreased appetite, white blood cell count decreased, amylase increased and hypoalbuminemia, primarily grade 1 or Nanjing/CN 14 Phase I Clinical Trial Ward, Zhejiang Cancer Hospital, Hangzhou/CN 2. Among the 55 patients with baseline ctDNA tested, 32 (58.2%) had detectable KRASG¹²D Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University mutation. Co-alterations were most frequently observed in TP53 (41.8%), BCL2L11 School of Medicine, Hangzhou/CN, ¹⁶Department of Medical Oncology, Central Hospital (20.0%,), STK11 (16.4%), KEAP1 (10.9%) and CDKN2A (10.9%). Updated data from approximately 75 patients with a minimum follow-up of more than 4 months will be Affiliated to Shandong First Medical University, Jinan/CN Department of Medical presented at the conference, along with genetic co-alteration analyses derived from NGS Oncology, Peking Union Medical College Hospital/Chinese Academy of Medical Sciences, profiling of baseline tumor tissue and paired baseline/end-of-treatment ctDNA samples. Beijing/CN, 18 Department of Medical Oncology, The First Affiliated Hospital of Anhui Conclusions: GFH375 exhibits compelling clinical efficay in patients with KRASG¹²D Medical University, Hefei/CN 19 GenFleet Therapeutics (Shanghai) Inc., Shanghai/CN mutant NSCLC, accompanied by a tolerable safety profile, warranting further clinical , 5:02 PM - 5:12 PM 10m View abstract development.

CCrozrX@CrozrX

Looking forward to 🫁 #WCLC26, where the emerging KRAS G12D landscape in NSCLC should come into sharper focus, especially with the expanded ~75-patient GFH375 dataset adding broader maturity, tumor NGS and paired ctDNA analyses to the current abstract snapshot.

Three approaches are already showing meaningful activity, but through distinctly different strategies: zoldonrasib, a G12D-selective RAS(O

563 impressions8 likes2 reposts2026-08-21

[Slide 1] GFH375 (China) vs VS-7375 (Global): ONE MOLECULE. TWO DEVELOPMENT PROGRAMS. TWO NEAR-TERM READOUTS. Advancing Selective KRASG12D (ON/OFF) inhibition in Previously Treated NSCLC Selective Strong efficacy Low-grade GI AEs Deeper follow-up, Next meaningful KRASG12D with emerging most common; NGS and paired VS-7375 update: (ON/OFF) inhibitor durability major TRAEs largely ctDNA analyses October 2026 attenuated after Cycle 1 upcoming GFH375 (China) — NSCLC VS-7375 (Global, Verastem) TOLERABILITY - VS-7375 (GLOBAL) WCLC 2025 vs WCLC 2026 UPDATE AUGUST 2026 CORPORATE PRESENTATION MAJOR TRAEs LARGELY ATTENUATED AFTER CYCLE 1 (≥29 DAYS) WCLC 2025 (Historical) WCLC 2026 UPDATE (Abstract OA02.01) EXPOSURE & RATIONALE 600 mg QD RP2D Subgroup 600 mg QD RP2D 900 mg QD achieves the targeted human AUCas in the majority 600 mg QD (N=57)4 900 mg QD (N=25)4 n = 53 evaluable patients n 16 (21 post-treatment tumor assessment) of patients, corresponding to maximal tumor regression KEY GI TRAEs Overall After Cycle 1 Overall After Cycle 1 across mouse models. (N=57) (N=51) (N=25) (N=22) All prior anti-PD-(L)1 + Population TARGET-D 101 (Mean Steady-State Exposure) Previously treated platinum-based chemotherapy (42.1% had >2 prior lines) Targeted 54% 24% 48% 18% 10,000 Diarrhea human AUCss 100 mg/kg G1:18% G3: 4% G1:12% G2:8% G3:4% G3: 0% 5.0 months (900 mg QD) (PR almost Minimum follow-up (no G2/3) - all mice) ORR (RECIST v1.1) 68.8% 54.7% (95% Cl: 42.6%-66.5%) Confirmed ORR - 49.1% (95% Cl: 37.1%-61.1%) VS-7375 (ng*h/mL) 1,000 30 mg/kg 51% 18% 52% 14% Nausea (Tumor regression G3: 2% G1:8% G2:10% G3: 4% G1:9% G3:5% in all models) DCR 93.8% 90.6% (95% Cl: 81.2%-96.2%) 100 10 mg/kg (Turner regression 37% 20% 24% 9% Median DoR 11.0 months (95% Cl: 5.6, NA) Vomiting - in sensitive models) G1:9% G3: 2% G1:14% G2:6% G3: 0% (no G2/3) 10 Median PFS - 8.1 months 400 mg QD 600 mg QD 900 mg QD (N=11) (N=73) (N=24) OTHER COMMON TRAEs (AFTER CYCLE 1) Median OS - 15.4 months Low-grade GI AEs 600 mg QD 900 mg QD TARGET-D 202 STUDY DESIGN (NSCLC) most common. (N=51) (N=22) Approximately ~75 patients with minimum follow-up >4 months will be presented at WCLC 2026, together with: Part A Part B: Part C Fatigue 12% 5% No Grade ≥4 GI TRAEs Tumor NGS profiling of baseline tissue 2L/3L NSCLC 2L/3L NSCLC 2L/3L/4L NSCLC at either dose overall Neutropenia 10% 0% Paired baseline / end-of-treatment ctDNA analyses Cohort A: Cohort B: or after Cycle 1. 900 mg QD with 900 mg QD Preferred dose asymptomatic Decreased appetite 4% 5% Major TRAEs largely Study population (WCLC 2026 Update): (N=20) of VS-7375 untreated brain attenuated after Cycle 1 All previously treated patients; all received prior anti-PD-(L)1 Anemia 6% 5% CONFIRM (N=60) metastases on both 600 mg and and platinum-based chemotherapy. 42.1% had >2 prior systemic lines. 900 mg QD is the (N=25) 900 mg QD. GO-FORWARD DOSE Post-Cycle 1 analysis includes patients followed >29 days SAFETY GFH375 (China) WCLC 2026 (600 mg QD) Enrollment expected to complete by end of 2026. (600 mg NoS1: mg N=22). Overall-treatment N=57 and N=25, respectively. Descriptive comparsion; differing denominators. KEY SAFETY OUTCOMES MOST COMMON TRAEs (>20% of patients)3 CLINICAL ILLUSTRATION - U.S. NSCLC PATIENT (KRASG12D) Denominators reflect all patients who received 21 dose. Grade >3 TRAEs 33.3% Diarrhea, vomiting, nausea, AST T. 77-year-old female Baseline Week 6 Week 12 Serious AEs 17.5% hypertriglyceridemia, ALT T. anemia, 600 mg QD (SLD 69 mm) uPR (-34%) cPR (-49%) TWO COMPLEMENTARY NEAR-TERM READOUTS neutrophil count 1. hyponatraemia, Prior therapy: TRAE discontinuation 1.8% proteinuria, decreased appetite, Pembrollzumab SEPTEMBER 2026 WCLC Dose reduction 21.1% WBC count 1. amylase T. (SD months) GFH375 (China) Update OCTOBER 2026 - VERASTEM hypoalbuminemia. Dyspnea and tumor pain Dose interruption 31.6% improved within 2 weeks Primarily Grade 1-2 of dosing ~75 patients (min. follow-up >4 months) Next meaningful TEAE: diarrhea G3 Tumor NGS and co-alterations Dose reduced in cycle 3 Paired baseline / end-of-treatment VS-7375 clinical update to 400 mg for 4 weaks Re-escalated to 600 mg ctDNA analyses after in cycle 4 single patient; not representation of cohort-level efficacy or tolerability. GFH375 demonstrates substantial activity with emercjng durablity at 600 mg RP2D in previously treated NSCLC. DOES IT LAST? CAN EXPOSURE DOES TOLERABILITY uPR: unonfirmed PR THE TAKEAWAY VS-7375 is advancing dose optimization toward 900 mg, achieving 49.1% confirmed ORR BE OPTIMIZED? EVOLVE? cPR: confirmed PR targeted exposures in most patients, while major TRAEs were 11.0 mo median DoR 900 mg achieves targeted AUCss in the majority Major TRAEs largely SD: stable disease largely hancy attenuated after Cycle 1. 8.1 mo median PFS attenuated after Cycle 1 DOF: data cutoff of patients Sources: 1. Verastem Oncology Corporate Presentation August 2026 (VS-7375 data). 2. WCLC 2026 Abstract OA02.01 GFH375 (China). Abbreviations: ORR, objective response rate; DCR, disease control of response; PFS, progression-free survival; Data cutoffs: June 2026 3. TRAEs occurring in >20% of patients. 4. Data cutoff: June 12, 2026. OS, overall survival; TRAE. treatment-related adverse event: AUC.., area under the curve at steady state; NGS, next-generation sequencing: For educational informational purposes only. ctDNA, circulating tumor DNA: QD. once daily. [Slide 2] THREE WAYS TO TARGET KRAS G12D IN NSCLC Confirmed response Unconfirmed response Latest Public Data Comparison (August 2026): Mechanisms Differ. Patient Populations Differ. Context Matters. NE: Not estimable NR: Not reached ON GFH375 / VS-7375 ZOLDONRASIB SETIDEGRASIB (ASP3082) (VERASTEM) (REVOLUTION MEDICINES) (PROTAC / ASTELLAS) SELECTIVE KRAS G12D KRAS G12D SELECTIVE KRAS G12D TARGETED OFF ON/OFF INHIBITOR RAS(ON) TRI-COMPLEX INHIBITOR PROTEIN DEGRADER ROUTE / PLATFORM Oral Once Daily (QD) ROUTE / PLATFORM Oral Once Daily (QD) ROUTE / PLATFORM IV Once Weekly (QW) WCLC 2026 ABSTRACT AACR 2026 . CT021 NEJM 2026 (PHASE 1) + ASTELLAS UPDATE PATIENT POPULATION & CONTEXT PATIENT POPULATION & CONTEXT PATIENT POPULATION & CONTEXT Safety population: N = 57 NSCLC patients Expanded Efficacy population: n = 272 NSCLC efficacy population: n = 45 at RP2D ASTELLAS 2L/3L Efficacy evaluable: n = 53' ~75-patient dataset KEY DESIGN All prior platinum + ICI (600 mg IV weekly)3 SUBGROUP UPDATE3 All prior anti-PD-1/PD-L1 + platinum chemotherapy with NGS and DIFFERENCE No prior docetaxel allowed Previously treated advanced NSCLC ORR 37.5% (95% CI 24.9 51.0) 42.1% had >2 prior systemic lines paired ctDNA Previously treated advanced NSCLC No prior docetaxel (multiple prior lines allowed) mPFS 11.2 months All metastatic at baseline; 94.7% adenocarcinoma analyses expected (95% 6.8 NE) allowed in Median follow-up: 13.1 months Population allowed prior multiple lines at WCLC 2026. Median follow-up: 9.7 months Minimum follow-up: 5.0 months efficacy population. Definition may include responses awaiting confirmation. KEY EFFICACY OUTCOMES (n=53 evaluable) KEY EFFICACY OUTCOMES (n=27) KEY EFFICACY OUTCOMES (600 mg IV weekly) ORR 54.7% (95% CI 42.6 66.5) Confirmed ORR 52% (95% CI 32 71) ORR / PR Rate 36% (95% CI 22 51) PATIENT-LEVEL PATIENT-LEVEL (All responses were PRs) Confirmed ORR 49.1% (95% CI 37.1 61.1) DCR 93% (95% CI 76 99) RESPONSE DATA DCR RESPONSE DATA — DCR 90.6% (95% CI 81.2 - 96.2) Median DoR NE (95% CI 8.3 NE) Patient-level response Median DoR - Patient-level response Median DoR 11.0 months (95% NA) Median PFS 11.1 months (95% CI 5.3 NE) and treatment-duration Median PFS 8.3 months and treatment-duration (95% 4.1 NE) Median PFS 8.1 months 12-month PFS 48% data presented at data published (95% CI 27 66) 12-month OS 59% (95% CI 40 74) AACR 2026. in NEJM. Median OS 15.4 months 12-month OS 73% (95% CI 47 89) Median OS NE BIOMARKER SNAPSHOT (Baseline ctDNA) BIOMARKER SNAPSHOT (ctDNA Molecular Response) (n=15)⁵ BIOMARKER SNAPSHOT Baseline ctDNA (n=5S) Most frequent co-alterations (baseline) >50% KRAS G12D VAF clearance: 87% (13/15) Direct KRAS G12D protein degradation demonstrated Detectable KRAS G12D TP53 BCL2L11 STK11 KEAP1 CDKN2A 100% KRAS G12D VAF clearance: 73% (11/15) pharmacodynamically in paired tumor biopsies. 32 (58.2%) 41.8% 20.0% 16.4% 10.9% 10.9% ctDNA molecular response is being explored as a marker of benefit. SAFETY WCLC 2026 ABSTRACT (N = 57)2 SAFETY - AACR 2026 CT021 (1200 mg QD, N = 40)6 SAFETY - NEJM 2026 (600 mg IV weekly, N = 76) Grade >3 TRAEs 33.3% Most Common TRAEs (>20% of patients)3 Grade 3 TRAEs 13% Most Common TRAEs (All Grade) Any AE 100% Most Common TRAEs (All Grade) Serious AEs 17.5% Diarrhea, vomiting, nausea, AST increased, No Grade 4/5 TRAEs — Nausea 43% hypertriglyceridemia, ALT t. anemia, Grade >3 AE 42% Infusion-related reaction 80% Dose reduction 21.1% Dose interruption 31.6% neutrophil count 1, hyponatremia, Dose interruption 15% Vomiting 33% Any TRAE 93% Nausea 30% proteinuria, decreased appetite, WBC 1, Dose reduction 3% Diarrhea 30% Discontinuation 1.8% (1) AE discontinuation primarily grade 1 or 2. Discontinuation 5% Rash 18% 2 patients Infusion-related reactions were (2.6%) predominantly transient; Global VS-7375 context: 1200 mg QD has been cleared without DLTs; Mean relative dose intensity 94% No Grade 4/5 TRAEs reported AE-related discontinuation was uncommon. at 600/900 mg, major TRAEs were largely attenuated after Cycle 1. CROSS-TRIAL CONTEXT PRIOR TREATMENT SUMMARY ROUTE & PRACTICAL DIFFERENCE DURABILITY SNAPSHOT (mPFS reported) CNS CONSIDERATION WHAT'S NEXT? Efficacy comparisons are limited by GFH375: all prior platinum + anti-PD-1/PD-L1; Zoldonrasib 11.1 months GFH375 / VS-7375 Oral QD Intracranial activity GFH375: -75-patient update at WCLC 2026 with NGS differences in patient selection, prior 42.1% >2 prior lines Setidegrasib 8.3 months remains a key variable. and paired ctDNA treatment, and follow-up maturity Zoldonrasib: prior platinum + ICI; Zoldonrasib Oral QD TARGET-D 202 (VS-7375) GFH375 8.1 months Zoldonrasib: continued not directly comparable. no prior docetaxel allowed prospectively includes follow-up Interpret across trials with care. Setidegrasib: multiple prior lines allowed Setidegrasib IV QW Follow-up maturity differs substantially. a cohort with asymptomatic Setidograsib: Phase 3 Cross-trial ranking is not established. untreated brain metastases. NSCLC monotherapy study being prepared for initiation in FY2026. 1. Efficacy evaluable patients: post-treatment tumor assessment 4. NSCLC efficacy population at 1200 mg QD. 7. NSCLC efficacy population at RP2D (600 mg IV weekly). Sources: GFH375 WCLC 2026 Abstract (OA02.01) 2. Safety population in NSCLC. S. ctDNA avaluable patients with paired baseline and on-treatment samples. 8. Safety population at 600 mg IV weekly. Zoldonrasib AACR 2026 (CT021): Setidegrasib NEJM 2026; For educational / informational 3. TRAEs are treatment-related adverse events. 6. Safety population at 1200 mg QD. Astelias press release Unly 31, 2026). purposes only. Not for promotional use. Date GFK725 0/13. ляго. Communic Coe a funding follow-up 13.1 mal: Setidegrasib Feb 3. 2025.

22CROWN240 impressionsall primary8 engagements1 posts · 1 voices▾

LLung Cancers Today@Lung_Cancers

🫁 Catching up on #ASCO26 news ahead of #WCLC26?

👑 Don't miss this insightful interview with @TonyMok9, who joined us to unpack the 7-year data from CROWN!

➡️ Watch: https://t.co/mMypQTeBBX

#lcsm #ALK #NSCLC #ASCO2026 https://t.co/1zrkRsxK7T

240 impressions6 likes1 reposts2026-08-22

[Slide 1] M Today Lung Cancers Today Urban Well Lung Cancers Today Health docwirenews if GIOncologyNow Woman Today Today rology PW Times PHYSICIANS WEEKLY bct Breast Cancers GU OncologyNow He sussem Urban Health Cardio CareToday figure1 mashup MD Nep Today ASCO 2026: CROWN Trial Data

Who is setting the agenda

Pre-Conference Social Leaderboard

Accounts ranked by the reach they are generating ahead of the meeting, split by who they are. Finance and crypto accounts are excluded entirely — ticker traffic measures share price, not clinical voice.

45 accounts · 204,789 impressions

Hidehito HORINOUCHI@hhorinouchi

ABBV-1480, ADAURA, ARROS-1, ARTEMIS-008

89.6Kimpressions

1157engagements

51posts

gilberto lopes@glopesmd

ADAURA, ARROS-1, ARTEMIS-008, EVOKE-03

27.7Kimpressions

494engagements

24posts

Drew Moghanaki@drewmoghanaki

HALT, MAVERICK, NORTHSTAR

15.9Kimpressions

232engagements

4posts

Masahiro TORASAWA, MD. PhD.@m_torasawa

ADAURA, ARROS-1, ARTEMIS-008, EVOKE-03

14.2Kimpressions

122engagements

3posts

Minhua Chu@chuminhua432

ABBV-1480, HARMONi-6, sac-TMT

6.9Kimpressions

81engagements

4posts

Laura Alder, MD@lauraaldermd

ARTEMIS-008, DeLLphi-309, MAVERICK, TAISHAN-302

4.3Kimpressions

44engagements

2posts

Uğur Özkerim@uozkerim

ADAURA, ARROS-1, ARTEMIS-008, EVOKE-03

4.2Kimpressions

93engagements

1posts

Giannis Mountzios@g_mountzios

EVOKE-03

4.2Kimpressions

54engagements

1posts

Jose Fernando Moura, PhD@fernandoonco

—

3.9Kimpressions

63engagements

2posts

Brendon Stiles@brendonstilesmd

—

3.5Kimpressions

23engagements

2posts

Dr Riyaz Shah@drriyazshah

ADAURA, ARROS-1, PAPILLON, REZILIENT3

2.9Kimpressions

53engagements

4posts

Kazuo@kayaba_mo

ABBV-1480, ARTEMIS-008, TAISHAN-302

2.9Kimpressions

26engagements

1posts

Balazs Halmos@balazshalmosmd

—

2.6Kimpressions

48engagements

1posts

Rami Manochakian MD, FASCO@rmanochakian

—

2.4Kimpressions

77engagements

1posts

Dr. Antonio Calles 🫁🚭@tony_calles

HARMONi

2.1Kimpressions

28engagements

1posts

Chinmay Jani@jani_chinmay

—

2.1Kimpressions

24engagements

2posts

Sabita Jiwnani@drsabita

—

2Kimpressions

23engagements

1posts

Dr. Estela Rodriguez@latinamd

ADAURA, ARROS-1, ARTEMIS-008, DESTINY-Lung04

1.8Kimpressions

35engagements

3posts

Michel Doepke@doepke_michel

ABBV-1480

1.7Kimpressions

8engagements

1posts

Stephen V Liu, MD@stephenvliu

—

1.2Kimpressions

14engagements

1posts

Lei Deng, MD (He/Him)@leideng3

—

1.1Kimpressions

21engagements

2posts

Dr. Nagla Abdel Karim@naglaakarimmd

—

1Kimpressions

17engagements

1posts

Patrick Forde@fordepatrick

—

1Kimpressions

26engagements

1posts

Dr. Fabio Moraes@fabiomoraesmd

—

813impressions

22engagements

1posts

Pharma Jonpi . / 1.1 / .@pharma_jonpi

—

671impressions

0engagements

5posts

Mara Antonoff, MD, FACS@maraantonoff

—

635impressions

0engagements

1posts

Banancial@banancial

HARMONi

498impressions

1engagements

1posts

Dr Alexey Kulikov@kulikovuniatf

—

455impressions

2engagements

1posts

Devika Das, MD, MSHQS, FASCO@devikadasmd

—

374impressions

6engagements

1posts

Sabine MD@nature_sabine

—

369impressions

3engagements

1posts

Dr. Hemalatha Ramachandran@hemrams

—

361impressions

3engagements

2posts

Dr. CFA|CMT (PhD)@flippyfloppy52

—

329impressions

1engagements

1posts

Jianjiao Ni@nijianjiao77941

—

320impressions

1engagements

1posts

EGFR Positive Lung Cancer UK@egfruk

HARMONi

169impressions

3engagements

1posts

Simon C@scserendipity1

—

165impressions

5engagements

1posts

Vandana Mahajan@oceanblue11oct

—

140impressions

4engagements

1posts

버섯돌이(Taehyun Kim)@mushman1970

—

81impressions

0engagements

1posts

L2P Research Labs@l2presearch

—

63impressions

0engagements

1posts

Vivek Tomar #RiseToSurviveCancer@r2survivecancer

—

54impressions

1engagements

1posts

Lucinda Burke@lucindaburke

—

48impressions

0engagements

1posts

Neil Newman@nbn426

—

47impressions

3engagements

1posts

Molecule Trader@molecule_trader

BNT327 (pumitamig)

46impressions

1engagements

1posts

Augustcool Research@augustcool

—

45impressions

1engagements

1posts

Oncology Resource Group (ONCrg)@onc_rg

—

25impressions

1engagements

1posts

Charlotte@charlotte281877

—

23impressions

0engagements

1posts

5 accounts · 22,130 impressions

IASLC@iaslc

—

18.5Kimpressions

271engagements

12posts

Lung Cancer Europe@lungcancereu

—

2.4Kimpressions

33engagements

1posts

Lung Cancer Research Foundation@lcrf_org

—

693impressions

17engagements

1posts

Grupo Español de Cáncer de Pulmón@gecp_org

—

499impressions

9engagements

2posts

Singapore Society of Oncology@sso_singapore

—

72impressions

1engagements

2posts

12 accounts · 8,117 impressions

LARVOL@larvol

—

2.4Kimpressions

61engagements

4posts

OncoDaily Lung@oncodailylung

—

2.3Kimpressions

65engagements

5posts

VJ Oncology@vjoncology

—

1.4Kimpressions

2engagements

3posts

OncoDaily@oncodaily

—

652impressions

6engagements

4posts

PER@gotoper

—

464impressions

12engagements

1posts

PeerView@peerview

—

288impressions

18engagements

1posts

Lung Cancers Today@lung_cancers

CROWN

240impressions

8engagements

1posts

Business-News-Today.com@bntbriefing

REZILIENT3

120impressions

1engagements

1posts

Guideline Central@guidelinecent

—

100impressions

0engagements

1posts

cGxP Wire@cgxpwire

—

77impressions

0engagements

2posts

Surgical Techniques Development MDPI@surgicaltd_mdpi

—

43impressions

1engagements

1posts

Conference Agendas@confagendas

—

30impressions

0engagements

2posts

5 accounts · 6,820 impressions

BioNTech SE@biontech_group

—

3.8Kimpressions

63engagements

1posts

AbbVie@abbvie

—

2.3Kimpressions

12engagements

1posts

Flatiron Health@flatironhealth

—

402impressions

1engagements

1posts

Cullinan Therapeutics@cullinantx

REZILIENT3

295impressions

9engagements

1posts

Henlius@henliusbiotech

—

76impressions

0engagements

1posts

Deep dives

Key Threads

Full multi-part previews from global KOLs, captured as complete conversation trees. Hashtag search alone only finds the first and last post of a thread — the substance sits in the middle parts, which carry no hashtag.

gilberto lopes@GlopesMd · 2026-08-21

6-part thread · 11.4K impressions

Presidential Symposium 1 — four phase III questions

MAVERICK/SWOG S1827 · TAISHAN-302 · ARTEMIS-008 · EVOKE-03

1/6 Alright! Three weeks to go @iaslc #WCLC26
Presidential Symposium 1 looks like a fascinating Sunday morning in Seoul.

Four phase III trials. One could change a decades-old approach to brain radiation, two test a new drug class in SCLC, and one may explain why promising phase II data didn’t survive phase III.

Here’s what we know — and what we’ll learn.

@OncoAlert @OncBrothers @Latinamd @COlazagasti @Jani_Chinmay #LCSM

4.5K impressions · view on X ↗

2.4K impressions · view on X ↗

595 impressions · view on X ↗

793 impressions · view on X ↗

920 impressions · view on X ↗

6/6 So Presidential Symposium 1 gives us four very different questions:

1. Can we safely use less radiation?

2. Can B7-H3 ADCs establish a new treatment class in SCLC?

3. Why did a promising ADC + IO strategy fail in phase III?

Sometimes the most important trials tell us what to stop doing — not just what to add.

See you Sunday morning in Seoul. 🇰🇷 #WCLC26

1.2K impressions · view on X ↗

4 replies in the thread

Devika Das, MD, MSHQS, FASCO @DevikaDasMD

@GlopesMd Hate to be missing it but looking forward to keeping up with the updates via this platform and #lcsm community!

Sabine MD @nature_sabine

@GlopesMd @IASLC The phase II to III translation issue is what I'll watch most closely. Those failures usually teach us more about trial design than the successes do.

Simon C @scserendipity1

@GlopesMd @EladSharonMD Sad not to be there but Gilberto is making up for that. Hope to see you at ESMO @OpenMedInsights

Neil Newman @nbn426

@GlopesMd Yes! Like the Japanese 2017 Ph3 I bet this will show safe to observe and treat when metastases present. Excited to see results

gilberto lopes@GlopesMd · 2026-08-22

6-part thread · 6.5K impressions

Presidential Symposium 2 — targeted therapy moving earlier

ADAURA 8-year · PAPILLON · REZILIENT3 · ARROS-1

1.9K impressions · view on X ↗

1.3K impressions · view on X ↗

1.1K impressions · view on X ↗

735 impressions · view on X ↗

5/6 ARROS-1

One I’m particularly looking forward to — and I’m pleased to be a co-author.

Zidesamtinib is a next-generation ROS1 inhibitor designed for potent CNS activity and resistance coverage.

Preliminary TKI-naïve ARROS-1 data were striking:

ORR 89%
Intracranial ORR 83% in a small evaluable CNS cohort.

Now WCLC brings updated efficacy and safety in the TKI-naïve population.

The big question: could zidesamtinib ultimately move into first-line ROS1+ NSCLC?

919 impressions · view on X ↗

6/6 Presidential Symposium 2 tells a larger story about where precision oncology is going:

➡️ targeted therapy after surgery
➡️ targeted therapy + chemotherapy upfront
➡️ competing strategies for the same genomic subgroup
➡️ next-generation drugs designed for the brain and resistance

We’re no longer asking simply “Can we target this alteration?”

We’re asking:

Which drug? When? In what sequence? And how early can we use it?

That’s a good sign of how far lung cancer has come. #WCLC26

680 impressions · view on X ↗

Where the attention sits

Themes

Mechanism and setting themes across the same corpus. A post can carry more than one.

EGFR

53.9K impressions · 39 posts

SCLC

50.6K impressions · 40 posts

Perioperative / Neoadjuvant

36.7K impressions · 20 posts

ADCs

33.6K impressions · 23 posts

Radiation / SBRT

30K impressions · 9 posts

Bispecifics / PD-1xVEGF

24.4K impressions · 20 posts

KRAS

15K impressions · 11 posts

ALK / ROS1

14.9K impressions · 12 posts

What’s coming

Session Previews & Watchlists

Agenda cards, symposium roundups and multi-trial watchlists — posts about what is about to be presented rather than what has been shown. They are the bulk of pre-conference reach, and they are counted separately from primary content throughout this page: a roundup naming four trials would otherwise hand its full audience to all four, letting a trial with no data out-rank one with a published readout.

HHidehito HORINOUCHI@HHorinouchi

7.3K impressions51 likes14 reposts2026-08-20

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

6.2K impressions27 likes10 reposts2026-08-19

HHidehito HORINOUCHI@HHorinouchi

5.4K impressions13 likes8 reposts2026-08-21

HHidehito HORINOUCHI@HHorinouchi

5K impressions47 likes20 reposts2026-08-21

HHidehito HORINOUCHI@HHorinouchi

4.8K impressions35 likes11 reposts2026-08-20

HHidehito HORINOUCHI@HHorinouchi

🆙 #WCLC26 #LCSM Mini Oral Session
🔥 Neoadjuvant Chemo-Immunotherapy vs EGFR-TKI in EGFR-Mutant NSCLC: TP53 as the Predictive Biomarker
🎯Chemo-ICI vs. EGFR-TKI
🎯Overall: pCR (19.6% vs 3.0%), MPR (41.2% vs 20.2%)
🎯TP53-mutant pts: MPR (48.6% vs 9.6%)
🎯TP53-WT pts: MPR (23.1% vs 38.7%)
🎙️ Dr. F. Wang
🔢 MO06.04
🔗 https://t.co/6rnqfaalhV
@OncoAlert @Larvol @IASLC @EGFRResisters

4.5K impressions21 likes7 reposts2026-08-27

[Slide 1] Comparison of PCR Rates Comparison of MPR Rates M006.04. Neoadjuvant Chemo-Immunotherapy VS EGFR-TKI in EGFR-Mutant NSCLC: Between Treatment Groups Between Treatment Groups TP53 as the Predictive Biomarker for Treatment Selection 50 25 P 0.011* F. Wang, W-Z. Zhong 41.2% P 0.002* (21/51) Guangdong Provincial People's Hospital, Guangzhou/CN , 3:55 PM 4:00 PM 19.6% (10/51) 40 20 5m View abstract Introduction: Neoadjuvant therapy for resectable EGFR-mutant NSCLC remains undefined. 30 While ADAURA established adjuvant osimertinib, the optimal neoadjuvant approach is PCR Rate (%) 15 MPR Rate (%) 20.2% unclear. Current guidelines recommend platinum-based chemotherapy + immunotherapy (20/99) 10 20 regardless of EGFR status, but emerging studies explore EGFR-TKI preoperatively. No validated biomarker guides selection between EGFR-TKI and chemo-immunotherapy 3.0% 10 (Chemo-IO). We hypothesized that genomic alterations may interact with treatment modality 5 (3/99) to predict major pathological response (MPR). Methods: Retrospective analysis of 150 EGFR-mutant stage IIA-IIIB NSCLC patients (2020- 0 0 Targeted Therapy Chemo-immunotherapy Targeted Therapy Chemo-immunotherapy 2025) receiving neoadjuvant therapy. Cohort: EGFR-TKI monotherapy (n=99) versus Chemo- (n=99) (n=51) (n=99) (n=51) IO n=51,upfront or sequence). Interaction logistic regression models: logit(P(MPR)) = ßo + Comprehensive Analysis of Gene-Treatment Interactions in EGFR-Mutant NSCLC (TP53 as the Only Significant Predictive Biomarker) A. Interaction Effects Between High-Frequency Mutations and Treatment (Forest Plot sorted by P-value) 31-Treatment + ß2-Gene +B3-(TreatmentxGene), followed by Bonferroni correction and Bootstrap validation (n=1000). Gene Forest Plot Statistics Results: Among 318 genes analyzed, only TP53 demonstrated significant interaction with OR 95% CI P-value TP53 0.002 treatment modality (interaction term P=0.002, OR=0.054, 95%CI: 0.008-0.345), remaining MDM2 5.020 3.040 0.351 significant after Bonferroni correction (P=0.023). In the overall population, Chemo-IO SMAD4 4.001 0.390 CDK4 1068 0.493 achieved significantly higher PCR rates than EGFR-TKI (19.6% VS 3.0%, P=0.002) and higher MYC 2.073 PIKICA 2.176 3.524 MPR rates (41.2% VS 20.2%, P=0.011). However, TP53 stratification revealed a complete 1.569 0.522 therapeutic effect reversal: TP53 wild-type patients (n=44) showed superior MPR with EGFR- 1.431 ARM10 1.044 TKI (38.7% VS 23.1% with Chemo-IO), whereas TP53 mutant patients (n=87) demonstrated 17" " Deds Ratio 10R, leg scale) dramatically higher MPR with Chemo-IO (48.6% VS 9.6% with EGFR-TKI)-representing a 5.1- 0. Predicted MPR Probability MPR Rate in wild type Patients MPR Rate in Mutant Patients (Heatmap) fold advantage for Chemo-IO in this subgroup. The absolute risk reduction for selecting Demo 10 Chemo-IO over EGFR-TKI in TP53 mutant patients was 39.0% (NNT=2.6). Bootstrap 2 TP53 Wild-type validation confirmed model stability (AUC=0.708, 95%CI: 0.659-0.724). Multigene models 23.1% 38.7% (note) : incorporating MDM2 or RB1 did not improve predictive performance compared to TP53 2 2 ! I I Kale alone (P>0.3). Conclusions: While EGFR-TKI remains the de facto standard for neoadjuvant therapy in : ress Nature 48.6% 9.6% EGFR-mutant NSCLC, our findings challenge this paradigm: TP53 wild-type patients benefit (n-87) to $ from EGFR-TKI (MPR 38.7%), whereas TP53 mutant patients achieve substantially superior responses with Chemo-IO (48.6% VS 9.6%). As TP53 mutations represent the predominant , / / / / / / Chema-10 Targeted Therapy Gene molecular subtype in this population, routine TP53 testing should guide treatment selection Pathological between these two modalities. interaction 0.002

ggilberto lopes@GlopesMd

1/6 Alright! Three weeks to go @iaslc #WCLC26
Presidential Symposium 1 looks lik

4.5K impressions42 likes16 reposts2026-08-21

[Slide 1] IASLC 2026 World Conference on Lung Cancer SEPTEMBER 12 - 15, 2026 I SEOUL, REPUBLIC OF KOREA I'M SPEAKING AT #WCLC26 Joining the World's Thoracic Cancer Experts in Seoul! 2 a Gilberto Lopes Sylvester Comprehensive Cancer Center wclc.iaslc.org United States

HHidehito HORINOUCHI@HHorinouchi

4.3K impressions33 likes11 reposts2026-08-21

UUğur Özkerim@UOzkerim

4.2K impressions51 likes18 reposts2026-08-20

GGiannis Mountzios@g_mountzios

4.2K impressions34 likes8 reposts2026-08-20

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

4.1K impressions33 likes9 reposts2026-08-19

MMasahiro TORASAWA, MD. PhD.@M_Torasawa

3.9K impressions12 likes1 reposts2026-08-20

JJose Fernando Moura, PhD@FernandoOnco

WCLC 2026: os 40 estudos de câncer de pulmão que estou de olho 👀 @GBOT_Alerta @IASLC #wclc26 https://t.co/avHjddTWok

3.5K impressions45 likes7 reposts2026-08-22

[Slide 1] WCLC 2026 TOP 10 01 NSCLC EARLY ESTUDOS Doença ressecável e estágio III com intenção curativa 1 OA04.02 IMpower030 Final Analysis Atezolizumab + quimioterapia perioperatória em NSCLC estágio II-IIIB. 2 Fase III em NSCLC EGFR-mutado: OA04.01 Adjuvant Gefitinib + Chemotherapy gefitinib + QT VS QT. 3 M006.01 NAUTIKA1 - Neoadjuvant Alectinib Alectinib neoadjuvante em ALK+ ressecável (IB-IIIB). 4 OA04.03 NAUTIKA1 Divarasib KRAS G12C como alvo no cenário neoadjuvante. 5 OA09.03 JS207 + Chemotherapy Bispecifico PD-1/VEGF em estágio III irressecável. 6 M006.03 BNT116 mRNA Vaccine Vacina mRNA + cemiplimab + carbo/paclitaxel neoadjuvante. 7 M006.04 Chemo-IO vs EGFR-TKI Estratégias neoadjuvantes no EGFRm com TP53 como potencial biomarcador. 8 M006.08 SBRT + Chemoimmunotherapy Resultados de longo prazo da estratégia neoadjuvante multimodal. 9 PT1.08.04 ctDNA + TCR Diversity Seleção molecular/imunológica para consolidação no estágio III. MAIOR POTENCIAL 10 M006.02 Firmonertinib EGFR-TKI em estágio I EGFRm e DE IMPACTO múltiplos primários. Estudos selecionados pré-congresso com base nos abstracts disponíveis ate 22/08/2026. [Slide 2] WCLC 2026 TOP 10 02 NSCLC ADVANCED ESTUDOS Doença avançada/metastática - novas drogas e combinações 1 Inibidor de KRAS G12D em OA02.01 GFH375 / VS-7375 NSCLC avançado. 2 QA12.01 QLC1101 Segundo programa de KRAS G12D com dados de eficácia e segurança. 3 OA14 Pumitamig + Elfetabart Drozuntecan PD-L1/VEGF bispecifico + B7-H3 ADC. 4 OA14 RC148 / ABBV-1480 + Chemotherapy PD-1/VEGF bispecífico na primeira linha. 5 OA10.01 Expansão global de dose em Iza-Bren NSCLC metastático EGFR-mutado. 6 OA12.02 HS-10370 + Adebrelimab + QT Inibição de KRAS G12C já na primeira linha. 7 Amivantamab + lazertinib + OA12.03 AMIGO-1 pemetrexed sem platina. 8 M007.04 PRESERVE-003 Gotistobart Gotistobart VS docetaxel após PD-(L)1 no NSCLC escamoso. 9 OA10.02 SYS6010 + Enlonstobart Nova combinação em NSCLC sem alteração genômica acionável. MAIOR POTENCIAL 10 M007.06 Opamtistomig + Chemotherapy Bispecifico PD-L1 X 4-1BB DE IMPACTO em primeira linha. [Slide 3] WCLC 2026 TOP 10 03 SCLC LIMITED ESTUDOS Doença limitada (estádio I-III) 1 Estágio IIB-IIIB N2, com cirurgia M015.03 Neoadjuvant Serplulimab + EP após tratamento sistêmico. 2 P3.288 Serplulimab + Concurrent CRT Quimiorradioterapia concomitante seguida de manutenção. 3 - Adebrelimab + QT + Individualized RT Integração de imunoterapia e radioterapia individualizada. 4 Neoadjuvant Adebrelimab + EP Estratégia neoadjuvante - seguida de cirurgia. 5 M015.01 CXCL9+ DC / CXCR3+ Tregs Mecanismos imunológicos associados à resistencia à neoadjuváncia. 6 - MRD Dynamics Dinâmica de doença residual minima no SCLC neoadjuvante. 7 - Surgery After Immunologic Downstaging Papel da cirurgia após downstaging induzido por terapia sistêmica. 8 - Individualized RT + IO Novas estratégias para integração de radioterapia e imunoterapia. 9 Biomarker Selection for 10 + CRT Busca por seleção biológica no - tratamento multimodal. MAIOR POTENCIAL DE IMPACTO 10 ASTRUM-020 Programa pivotal a acompanhar no desenvolvimento do LS-SCLC. [Slide 4] WCLC 2026 TOP 10 04 SCLC EXTENSIVE ESTUDOS Doença extensa (estágio IV) 1 Administração subcutânea do M015.07 DeLLphi-308 SC Tarlatamab DLL3 T-cell engager. 2 ABBV-706 ADC dirigido a SEZ6, novo alvo de grande interesse no SCLC. 3 M015.02 QLC5508 + QL1706 / QL2107 ADC + imunoterapia em primeira linha. B7-H3 ADC + PD-1 4 M015.04 YL201 + Serplulimab na primeira linha. 5 Analise de manutenção P3.317 ASTRUM-005 Maintenance com serplulimab. 6 CAR-T autólogo dirigido a DLL3 OA05.01 LB2102 - DLL3 CAR-T e armado com dnTGFBR2. 7 Combinação racional baseada em M015.06 ADC + ATR Inhibition / SLFN11 dano ao DNA e biomarcador. 8 M015.05 B7-H3 Expression Expressão e valor prognóstico de B7-H3 no SCLC. 9 M015.08 cfDNA Methylation Biomarcador de imunoterapia, incluindo pacientes com metástases hepáticas. MAIOR POTENCIAL 10 M015.09 CT Biomarkers for Tarlatamab Toxicity Predição de CRS/ICANS por DE IMPACTO biomarcadores de imagem.

HHidehito HORINOUCHI@HHorinouchi

3.1K impressions29 likes6 reposts2026-08-20

KKazuo@kayaba_mo

2.9K impressions22 likes2 reposts2026-08-23

HHidehito HORINOUCHI@HHorinouchi

2.8K impressions12 likes4 reposts2026-08-22

ggilberto lopes@GlopesMd

#WCLC26 @iaslc
Looking forward to meeting you in Seoul
On behalf of @Jani_Chinmay I will be presenting our study showing that ctRNA added to liquid biopsy increased the detection of actionable alterations by 38%!

@OncoAlert @OncBrothers @oncodaily
@LucenceHealth https://t.co/vPN44lDxnb

2.4K impressions43 likes14 reposts2026-08-22

[Slide 1] MO11.05. Enhanced Detection of Actionable Fusions in NSCLC Using Combined ctDNA and ctRNA Analysis C.T. Jani¹, L. Negret², S. Dormady³, 0. Gligich⁴, D. Bryson⁵, S. Singhal³, J. Poh⁶, H. Kittur⁶, M-H. Tan⁶, G. Lopes² 1 University of Miami, Sylvester Comprehensive Cancer Center, Miami/FL/USA, ²Sylvester Comprehensive Cancer Center, MIAMI/FL/USA, ³El Camino Health, Mountain View/CA/USA, Mount Sinai Medical Center, Miami/FL/USA ,⁵Bryson Cancer Care Center, Visalia/CA/USA ⁶Lucence, Palo Alto/CA/USA 1 11:20 AM - 11:25 AM I 5m View abstract View biography [Slide 2] Enhanced Detection of Actionable Fusions in NSCLC Using Combined ctDNA and ctRNA Analysis Introduction: Comprehensive genomic profiling is critical in non-small cell lung cancer (NSCLC) to identify actionable alterations, particularly gene fusions that inform targeted therapy selection. While circulating tumor DNA (ctDNA) assays are widely used, fusion detection in liquid biopsy remains challenging due to structural complexity and low analyte abundance. Circulating tumor RNA (ctRNA) may enhance detection by capturing expressed fusion transcripts, but real-world evidence of its added value is limited. Therefore, our study aimed to evaluate whether combined ctDNA and ctRNA analysis improves detection of actionable alterations in NSCLC. Methods: We performed a retrospective analysis of plasma samples from NSCLC patients who underwent real-world clinical testing using the LiquidHALLMARK ctDNA and ctRNA liquid biopsy assay. Samples were collected between September 2021 and February 2026. The primary endpoint was detection of actionable alterations, defined as pathogenic variants associated with guideline- recommended or FDA-approved therapies in NSCLC. Detectable alterations in ctRNA included fusions and MET exon 14 skipping alterations. Fusion detection was compared between ctDNA alone and combined ctDNA+ctRNA. [Slide 3] Results: A total of 602 patients from 625 samples were included; 52.4% were female, 75.9% were aged ≥60 while 7.0% were aged <50 years. Patients were from the United States (58.5%) and Asia (41.5%). Overall, 38.5% (232/602) of patients harbored ≥1 actionable alteration (VAF range: 0.02%-94.54%), including 3.3% (20 patients) aged <50 years. There was a notable regional difference in patients who harbored an actionable alteration (58.0% in Asia vs 24.7% in the United States). The most frequent alterations were EGFR L858R/exon 19 deletions (23.1%), EGFR resistance mutations (4.3%), KRAS G12C (4.0%), and MET exon 14 skipping (2.2%). An actionable fusion or MET exon 14 skipping alteration was detected in 7.1% (43/602) of patients. Notably, 12 rearrangements were uniquely identified by ctRNA, enabling a 38.7% (12/31) relative increase in rearrangement detection compared to ctDNA alone. These included additional ALK (n=2), ROS1 (n=3), RET (n=5), MET exon 14 skipping (n=1), FGFR (n=1), and NRG1 (n=1) alterations. Conclusions: Integrating ctDNA and ctRNA analysis enhances detection of actionable alterations in NSCLC, with a 38.7% increase in gene fusion or MET exon 14 skipping detection over ctDNA alone. Incorporation of ctRNA expands identification of patients eligible for targeted therapies and meaningfully enhances the clinical utility of liquid biopsy. [Slide 4] Table 1. Percentage or number of samples (of 625) with actionable mutations by gene Mutation: N (%) ctDNA analysis ctRNA analysis ctDNA + ctRNA * EGFR L858R and exon 19 147 (23.5%) Not tested 147 (23.5%) deletions EGFR exon 20 insertions 9 (1.4%) Not tested 9 (1.4%) EGFR G719/S768/L861 15 (2.4%) Not tested 15 (2.4%) EGFR resistance mutations 26 (4.2%) Not tested 26 (4.2%) ALK rearrangements 10 (1.6%) 7 (1.1%) 12 (1.9%) ROS1 rearrangements 3 (0.5%) 5 (0.8%) 6 (1%) RET rearrangements 7 (1.1%) 9 (1.4%) 12 (1.9%) BRAF V600E 2 (0.3%) Not tested 2 (0.3%) MET exon 14 skipping 13 (2.1%) 7 (1.1%) 14 (2.2%) MET amplification 3 (0.5%) Not tested 3 (0.5%) ERBB2 (HER2) 9 (1.4%) Not tested 9 (1.4%) KRAS G12C 24 (3.8%) Not tested 24 (3.8%) FGFR mutations 3 (0.5%) Not tested 3 (0.5%) FGFR rearrangements 0 (0) 1 (0.2%) 1 (0.2%) NTRK rearrangements 1 (0.2%) 0 (0%) 1 (0.2%) NRG1 rearrangements 0 (0) 1 (0.2%) 1 (0.2%) * "ctDNA + ctRNA combined testing" does not double-count a sample with a finding in both ctDNA and ctRNA.

ggilberto lopes@GlopesMd

2.4K impressions17 likes9 reposts2026-08-24

Every slide, tagged

Image Library

All slides and graphics shared by global KOLs, mirrored to our own CDN and grouped by the trials and themes their post names. A slide naming several trials appears under each, so the tag counts sum to more than the slide total. Click a tag to filter, or any image to expand. Conference branding and ticker charts are excluded.